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A superfamília de recetores scavenger ricos em cisteína é caracterizada por 
proteínas contendo domínios scavenger compostos por 100 aminoácidos com 
resíduos de cisteínas dispostos de uma forma bem conservada entre espécies. 
A superfamília encontra-se dividida em dois grupos, A e B, podendo as 
proteínas ser expressas em diversos tipos de células e serem secretadas ou 
estarem associadas à superfície celular mediando interações com outras 
proteínas e ligandos. Não há uma característica específica que unifique estas 
proteínas, exceto as propriedades estruturais dos domínios altamente 
conservados que apresentam. As proteínas pertencentes ao grupo SRCR B 
estão envolvidas em diversas funções como reconhecimento de patogénios, 
modulação da resposta imune, homeostasia do epitélio e desenvolvimento de 
tumores entre outros. Spα e S4D-SRCRB pertencem a este grupo. A proteína 
Spα tem sido associada a condições inflamatórias, como doenças metabólicas 
(aterosclerose e obesidade), cancro do pulmão e fígado, sendo também 
considerado um recetor de reconhecimento de patogénios para diversas 
bactérias e fungos. Apesar de estruturalmente semelhante ao Spα, pouco se 
sabe acerca do padrão de expressão da proteína S4D-SRCRB. As 
características de ambas proteínas Spα e S4D-SRCRB são importantes para a 
compreensão do tipo de papéis que estas proteínas têm na homeostasia do 
sistema imunitário. Enquanto que o papel de S4D-SRCRB permanece 
desconhecido, a importância de Spα como recetor de reconhecimento a 
patogénios e o seu envolvimento na inflamação foram já observados. No 
entanto, inúmeros mecanismos associados a estas proteínas permanecem 
desconhecidos.  
O objetivo deste trabalho foi, por conseguinte, estudar o papel destas 
proteínas na inflamação. Para tal, diferentes técnicas foram utilizadas para a 
caracterização da expressão destas duas proteínas, a nível tecidular e celular 
num estado de repouso. Após isto, foi analisado também a variação da 
expressão destas proteínas após estímulos inflamatórios e anti-inflamatórios 
dados a células de origem epitelial ou hematopoiética. 
Neste trabalho são reportadas novas localizações destas duas proteínas e 
demonstrado que a sua expressão parece ser diferente em resposta a 
condições de inflamação/anti-inflamação, sugerindo que possam ter um papel 
em diferentes localizações celulares e uma função na modulação da 
inflamação tanto na imunidade inata como adaptativa. Pela purificação da 
proteína recombinante Spα foi possível identificar células que expressam 
ligando(s) para esta proteína, um passo importante para entender a sua 
função. 
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abstract The scavenger receptor cysteine-rich (SRCR) superfamily is characterized by 
proteins containing scavenger domains composed of about 100 amino acids 
with cysteine residues placed in a highly conserved manner among species. It 
is divided into two groups, A and B. The proteins of this superfamily can be 
expressed in diverse types of cells and be secreted or cell surface-bound, 
mediating protein-protein interactions and binding to (a) ligand(s). There is no 
special feature that unifies these proteins, except for the structural properties of 
the highly conserved domains. SRCR B proteins are involved in diverse 
functions such as pathogen recognition, modulation of immune response, 
epithelial homeostasis and tumor development among others. Spα and S4D-
SRCRB belong to this group. Spα is being associated to inflammatory 
conditions, like metabolic disorders (atherosclerosis and obesity), liver and lung 
cancer, being a pattern recognition receptor for diverse bacteria and fungi. 
Although structurally similar to Spα, very little is known about the expression 
pattern and localization of S4D-SRCRB. The characterization of both Spα and 
S4D-SRCRB proteins is important to understand what kind of roles they have in 
the homeostasis of the immune system. While the role(s) of S4D-SRCRB 
remain largely unknown, the importance of Spα as a pattern recognition 
receptor (PRR) and its involvement in inflammation was already observed. 
Nonetheless, numerous mechanisms associated with these proteins remain 
unexplored.  
The goal of this work was therefore to study the role of these proteins in 
inflammation. For that, different detection techniques were used for the 
characterization of the expression of the two proteins, at the tissue and cellular 
levels in a resting state. Then the variation of these proteins expression 
depending on inflammatory and anti-inflammatory stimuli given to epithelial or 
hematopoietic-origin cells was also analyzed. 
In this work new localizations of these two proteins are reported and their 
expression was shown to be different in response to inflammatory/anti-
inflammatory conditions, suggesting that they may have a role in different 
cellular locations and a function in the inflammatory modulation of both innate 
and adaptive immunity. Through the purification of the recombinant Spα, it was 
possible to identify cells that express ligand(s) for this protein, an important 
step to understand its function. 
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Spα is a soluble scavenger receptor cysteine-rich (SRCR) protein expressed by macrophages from 
different tissues. A role of Spα as a putative pathogen-recognition receptor has been previously 
suggested, but additional pleiotropic functions such as viability support in lymphocytes during thymic 
selection, lipid metabolism or anti-inflammatory effects in autoimmune pathologies have also been 
ascribed to Spα. We have expressed recombinant Spα and determined that it displays increased binding 
to pathogenic bacterial strains and probably plays a part in host defense mechanisms against microbial 
invasion. To elucidate the role of Spα in an inflammatory context, we activated a human monocytic cell 
line using different agonists and found that stimuli associated with the triggering and resolution of 
inflammation induced significant changes in Spα protein levels. Furthermore, we identified several 
human cell lines of multiple types and origins that produce Spα, revealing that the action of this 
protein may be broader than anticipated, but in agreement with the high abundance of Spα in human 
serum. Given that the cellular targets and receptors for Spα remain unknown, we used Spα tetramers 
containing fluorescent streptavidin to perform a screening of binding of the protein to different cell 
lines, and multiple cells from epithelial origin seemed indeed to express a putative receptor (s) for Spα. 
Further characterization showed that the interaction is Ca2+ dependent, possibly inducing 
conformational changes in the Spα SRCR domains to stabilize the protein. Our evidence thus points to 
the participation of Spα in pathogen neutralization and in the control of inflammation. 
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1. The immune system 
 
The multicellular organisms have developed a defense system against pathogens that is 
able to distinguish between self and nonself molecules with the purpose of eliminating foreign 
threats. For that, the immune system comprises an array of cells and molecules that work 
together. The different cells that serve as effectors in the immune system originate in the bone 
marrow from pluripotent precursors: the hematopoietic stem cells. Classically, it is assumed 
that these cells can assemble two types of defense: innate and adaptive immunity [1, 2]. 
Nowadays, this separation is ambiguous or somewhat inaccurate because instead of working 
separately, the two defense systems cooperate to enhance the immune response. For example, 
cells belonging to the adaptive branch require signals from the innate immunity to be properly 
activated [3]. In order to simplify the explanation of the immune system, I will refer the two 
systems separately in the following sections. 
 
1.1. Innate Immunity – the first line of defense 
 
Innate immunity is an ancient first line of defense that provides a rapid and broad 
response to invading pathogens, independent from previous contact with foreign molecules, 
which also lacks immunologic memory. It is composed of physical (e.g., epithelial barriers) and 
chemical defenses (e.g., secreted mucus, soluble proteins, enzymes, membrane-bound pattern 
recognition receptors – PRR – that bind conserved pathogen-associated molecular patterns – 
PAMPs – expressed on the surface of pathogens). One fundamental aspect of innate 
immunity is that its quality and intensity does not change upon repeated interactions with 
pathogens [3, 4]. 
Granulocytes, mast cells, dendritic cells, natural killer cells and monocytes are the key 
players in establishing the innate immune response. 
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Granulocytes like neutrophils, eosinophils and basophils have a short life and are 
produced in a large scale. Neutrophils are the more abundant cell type and are responsible for 
the phagocytosis of microorganisms in an efficient way in early stages of inflammation. They 
produce reactive oxygen species – ROS – (cytotoxic for bacterial pathogens), neutrophil 
extracellular traps (capable of destroying extracellular bacteria) and can release granules in the 
extracellular environment to improve their response. Neutrophils can also produce enzymes 
for tissue repairing and remodeling after injury. They are cleared from the injured tissue by 
apoptosis. It is believed that eosinophils and basophils have a variety of enzymes and toxic 
proteins, acting against parasites that are hardly engulfed by neutrophils. Eosinophils can be 
found in large amounts in mucosal areas and are important in the triggering of allergic 
reactions and asthma. They are also very important in the combat of parasitic infection by 
antibody-dependent cell-mediated cytotoxicity. These cells can produce various cytokines and 
Figure 1: Cells from the immune system can be divided as belonging to innate or adaptive immunity. 
On the left are represented cells associated with the innate immune system: mast cells, dendritic cells, 
granulocytic cells, macrophages and natural killer cells. On the right are represented cells from the adaptive 
immune system, the T and B lymphocytes. In the middle of the scheme are γδ and natural killer T cells, 
cytotoxic lymphocytes found in the interface of these two defense systems. Adapted from Dranoff [1]. 
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pro-inflammatory mediators. Basophils can be found in smaller numbers representing only 1% 
of the peripheral blood leukocytes. They can be recruited to inflammatory sites, responding to 
immunoglobulin (Ig) E-antigen complexes and contribute to immediate hypersensitivity 
reactions. Mastocytes have a role in allergic and inflammatory responses, protecting internal 
surfaces of the organism against pathogens. Mast cells can be found in mucous membranes, 
under epithelial skin, blood vessels, having an important role in acute inflammation [5]. 
Monocytes may be found circulating in blood, bone marrow and spleen. They have an 
irregular shape, with a high cytoplasm-to-nucleus ratio. The circulating monocytes in the 
bloodstream migrate to tissues where they differentiate into macrophages – Mɸs. This 
differentiation is dependent on stimuli, which according to its nature can lead to a classical 
(M1 – a more pro-inflammatory phenotype) or an alternative activation (M2 – anti-
inflammatory phenotype) [6-8]. The polarization into one of these two types of macrophages 
differs in the in vivo and in vitro contexts. M1 Mɸs are differentiated in vitro upon bacterial 
infection or presence of IFN-γ, TNF-α, GM-CSF. This type of Mɸs can produce toxic 
molecules (reactive oxygen species – ROS and nitric oxide – NO), inflammatory cytokines 
(TNF-α, interleukin (IL)-1, IL-6, IL-12, IL-23) and mediate resistance against intracellular 
parasites and tumors. M2 macrophages differentiate in response to IL-4, IL-10, IL-13, TGF-β, 
M-CSF and glucocorticoids. This phenotype is more frequently associated with allergies, 
parasite clearance, tissue remodeling, angiogenesis and tumor promotion. However, these two 
phenotypes are not static and M2 can change between the heal and growth promoting stage 
(its metabolism pass from arginine to ornithine and polyamines, promoting cell proliferation 
and repair) to M1, a more killing and inhibitory stage (where the metabolism pass to NO and 
citrulline, providing a microbicidal activity and cell proliferation inhibitory capacity) [9]. In vivo 
the two macrophage phenotypes are not well defined and often macrophages present a mixed 
phenotype, which reflects the complexity and the continuous changes in tissue 
microenvironment [9]. 
Natural killer cells mediate the defense against cells infected by viruses (causing cell 
lysis), bacteria, protozoa and tumor cells. They are characterized by a wide response inducing 
the recruitment of macrophages and neutrophils, activation of dendritic cells and B and T 
lymphocytes [5]. 
Dendritic cells (DCs) are located in peripheral tissues like the skin, intestine and liver, 
where they get into contact with pathogens, or capture substances through phagocytosis. DCs 
are regulated by a myriad of cytokines derived from macrophages or natural killer cells. Also, 
6 
 
they have a detrimental role in the activation of certain T lymphocytes like γδT and NK T 
cells through presentation of lipid antigens. Besides the interaction with T cells, DCs can also 
coordinate B lymphocyte responses. Both Mɸs and dendritic cells make the connection 
between the innate and adaptive immunity by presenting antigens to B and T cells in the 
lymph nodes, being considered antigen presenting cells – APC. In the other hand, cells from 
adaptive immunity enhance the activation of the innate immunity resulting in an increased 
efficacy in eliminating foreign molecules/particles [5, 10]. 
Apart from the cells that serve as effectors to the immune system, cytokines are also 
an important group of soluble proteins released by immune cells and constitute another layer 
of complexity in this system. These proteins mediate the interactions between cells and allow 
the communication among them. Cytokines act like a hormone having an autocrine, paracrine 
or endocrine action. Their action may be synergic or antagonist and trigger signaling cascades, 
where one cytokine can induce the production of others cytokines [11]. 
Cytokines can be divided into the following subgroups: 
i) Pro-inflammatory cytokines – they are produced by activated macrophages, 
fibroblasts, endothelial cells, monocytes, dendritic cells and lymphocytes [12]. 
Their action involves up-regulation of inflammatory reactions. In an acute 
inflammation context, pro-inflammatory cytokines like IL-1 β and TNF-α play an 
important role, being considered potent inflammatory molecules that mediate this 
type of reaction induced by LPS (lipopolysaccharide), for example. 
ii) Anti-inflammatory cytokines – immunoregulatory molecules that control pro-
inflammatory cytokine production and secretion. IL-10 is produced by a variety of 
cells like macrophages, CD4+ T cells, activated CD8+ T cells and activated B cells, 
being considered an important anti-inflammatory stimulus. It is capable of 
inhibiting IFN-γ production by T cells, interrupt the synthesis of pro-
inflammatory cytokines by monocytes and macrophages, among other functions 
[13].  
iii) Chemokines – chemotactic cytokines that promotes activation and migration of 
leukocytes. Examples of this class of molecules are monocyte chemoattractant 
protein, IL-8 and lymphotactin [11]. 
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1.2. Adaptive Immunity – The specialized line of defense 
 
By contrast with innate immunity, the adaptive immune system represents a delayed 
but specific response, involving APCs that migrate to secondary lymphoid tissues where they 
will come into contact with B and T lymphocytes, activating these cells and originating a 
clonal expansion and memory. Naive lymphocytes are selected by its antigen specificity to 
differentiate into activated effector cells. The antigen specificity is provided by antigen specific 
receptors upon recombination of their genes, creating a myriad of cells whose receptors are 
capable of recognizing virtually any antigen [10]. 
The T cell receptor (TCR) is the 
antigen specific receptor expressed in T 
lymphocytes. The TCR only recognizes 
peptides, produced by proteolytic cleavage 
of antigens, when bound to the major 
histocompatibility complex (MHC) 
expressed in other cells. There are two 
types of MHC: class I and II. MHC class I 
presents molecules that are expressed in 
most cells of the organism and since they 
can collect peptides derived from cytosolic 
proteins, this allow the presentation of 
viral protein fragments at the surface. 
MHC class II molecules are only 
expressed by APCs and present peptides 
derived from endocytosed proteins that 
are subsequently degraded by acid-dependent proteases in endosomes. 
T lymphocytes can be distinguished according to the expression of the co-receptors 
CD4 and CD8. CD8+ T cells (also called cytotoxic T cells) are restricted to peptide 
presentation through MHC-I and are responsible for killing cells infected with intracellular 
pathogens. By contrast, CD4+ T cells (T helper cells) recognize antigenic peptides bound to 
MHC-II and regulate cellular and humoral immune responses [14]. 
The TCR is associated with invariant accessory chains, the CD3 complex, as shown in 
Fig. 2 [15]. When the TCR contacts with MHC it may induce modifications in the CD3 
Figure 2: Schematic representation of the initial 
signaling events triggered by the interaction of the 
TCR with the peptide-MHC complex (pMHC). 
Several molecules are recruited inducing a signaling 
cascade, which ultimately leads to clonal proliferation and 
differentiation of lymphocytes. Adapted from Malissen et 
al [15]. 
8 
 
complex, triggering phosphorylation and association with downstream proteins. CD3 chains 
have immune-receptor tyrosine-based activation motifs (ITAM) in the cytoplasmic domain 
that associate with the Src-family tyrosine kinase Fyn. For the activation to occur, the co-
receptors CD4 and CD8 bind to MHC molecules. These co-receptors have bound, in the 
cytoplasmic domain, another Src kinase leukocyte-specific tyrosine kinase – Lck – that 
phosphorylates the CD3 ITAMs. Another molecule named CD45 is important within this 
mechanism. CD45 contains a tyrosine phosphatase activity in the intracellular region that 
activates Lck and Fyn by removing the inhibitory phosphate groups from the kinases, thereby 
enabling their function in phosphorylating the CD3 ITAMs. These phosphorylations allow 
ZAP-70 (zeta-chain-associated protein kinase 70) docking, triggering a downstream cascade 
that will lead to the transcription of genes that control lymphocyte proliferation and 
differentiation [16]. 
However, for optimal T-cell stimulation, a second signal is required because when the 
TCR binds to an antigen-MHC complex, only a partial signal for cell activation is provided. 
To induce proliferation and other effector functions, a costimulatory molecule, like CD28, is 
required, that will bind to CD80 or CD86 expressed in the APC [3].  This kind of stimulation 
enhances TCR signaling in a quantitative way because CD28 binding will result in the 
recruitment of almost the same proteins involved in the signaling cascade recruited by the 
activated TCR complex as explained above [16]. 
B cells have immunoglobulin (Ig) as B 
cell receptors (BCR) that recognize antigens 
(native proteins and glycoproteins) and 
pathogens. The immunoglobulin is membrane 
bound, but upon activation, B cells start to 
secrete Igs (also known as antibodies). Igs are 
composed by two identical heavy chains and 
other two identical light chains, as represented 
in Fig. 3 [17]. There are five different types of 
heavy chains and each type originates one class 
of Ig: IgA, IgG, IgD, IgE and IgM. These 
chains have an amino-terminal portion that 
varies in the amino acid sequence from one 
antibody molecule to another, named variable region. Light and heavy chains loci are 
Figure 3: Schematic representation of an 
immunoglobulin. Adapted from Mesquita Junior 
et al [17]. 
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composed by variable gene elements (V), diversity segments (D) for the heavy chain gene 
only, joining segments (J) and constant region (C) exons.  The somatic combination of V-D-J 
creates the amino-terminal portion of each heavy chain. On the other hand, the combination 
of V-C genes creates the amino-terminal portion of the light chain. The variable region 
contains 3 subregions that are highly variable between different antibodies. When VDJ 
combine, a hypervariable region is formed which is important to the antigen-binding domain 
assembly.  
B cells are activated after binding of the BCR to an antigen that can be whole 
microorganism, proteins or polysaccharides, like LPS. After the antigen recognition, the B 
lymphocyte will proliferate and differentiate into plasma cells ultimately leading to the 
secretion of Igs [3, 10]. 
 
1.3. Inflammation and receptors from innate immunity 
 
In this non-specific response, 
both innate and adaptive immunity 
interact in order to fight pathogens 
and tissue malfunction by loss of 
homeostasis (injury, trauma or 
exposure to foreign particles), but 
with a particular difference: it can 
damage the self-tissue. Sometimes, 
this type of damage is deregulated 
leading to autoimmune diseases like 
multiple sclerosis, rheumatoid 
arthritis, type 2 diabetes, among 
others. 
Figure 4: Illustration of the first part of 
the inflammatory cascade. Some inducers 
(PAMPs or DAMPs) are necessary to initiate 
this cascade. The recognition is made 
through TLR or NLR. The pathway via TLR 
induces the separation of IkB (an inhibitory 
protein) from NF-kB, leading to the 
production of interleukins. NLR activate 
caspase 1, which converts cytokines into an 
active form. Adapted from Ashley et al [18]. 
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Once tissue dysfunction occurs, a highly conserved first response takes place, 
characterized by the recruitment of several repairing components, such as leukocytes, platelets 
or plasma proteins, increased fluid mediated by local vasodilation and an overall increase in 
blood flow [18]. 
The innate immune system relies on a limited number of invariable pathogen 
recognition receptors (PRR). These receptors recognize pattern-containing molecules 
expressed at the surface of the pathogen’s membrane, like LPS (expressed in Gram-negative 
bacteria), LTA (expressed in Gram-positive bacteria) and others. Upon ligand binding with the 
PRR, a cascade of events is triggered, resulting in the production of mediators (pro-
inflammatory, anti-inflammatory) that lead to eradication of the threat and the restauration of 
homeostasis. Thus, the inflammatory process begins with an inducer, which can be a PAMP 
or DAMP (damage-associated molecular pattern) and proceeds to their recognition by innate 
immunity through its receptors, as illustrated in Fig. 4 [19]. 
 
1.3.1. Toll-like receptors 
 
Toll-like receptors (TLR) are a family of transmembrane glycoproteins characterized 
by an extracellular domain containing leucine-rich repeats (LRRs) and a cytoplasmic tail that 
contains a conserved region called Toll/IL-1 receptor (TIR) domain. They initiate the 
expression of diverse host defense genes leading to the transcription of inflammatory 
cytokines and antimicrobial peptides. Nowadays, 13 different TLRs have been described, 
according to their ligand specificities and localization [20]. Some are expressed in the plasma 
membrane and recognize bacterial components, like TLR4 that together with CD14 binds 
LPS, or TLR2 that by forming heterodimers with TLR1/6 recognizes a vast number of ligands 
(peptidoglycans, LPS, a certain component of the yeast cell wall, etc.) [21]. Other receptors are 
localized in the endolysosomal membrane (TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, 
TLR13) where they can be activated by microbial nucleic acids. After the recognition made by 
these receptors, the pathway triggered leads to the activation of the transcription factor NF-kB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) providing a rapid release of 
inflammatory mediators [22]. 
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1.3.2. NOD-like receptors 
 
The nucleotide-binding oligomerization domain-like receptors (NOD like receptors-
NLR) constitute another family of PRRs. They are cytoplasmic receptors that can recognize 
PAMPs of internalized microbial components and DAMPs, frequently associated with cell 
stress, alerting the immune system to cell injury. The characteristic feature of NLRs is a central 
NOD (or NACHT) domain required for oligomerization, an N-terminal homotypic protein-
protein interaction domain and a C-terminal series of LRRs involved in agonist sensing or 
ligand binding. Sensing of such ligands by NLRs leads to their oligomerization into large 
macromolecular scaffolds inducing i) the rapid activation of NF-kB or MAP kinases 
culminating in the production of inflammatory cytokines, or ii) the activation of 
inflammasomes (supramolecular complexes for activation of inflammatory caspases by 
cleavage). NOD 1 and NOD 2 are examples of NLRs, involved in the recognition of 
peptidoglycans, diverse microbial pathogens, pathogenic protozoal parasites and may direct 
autophagy to eliminate intracellular bacterial pathogens [23]. 
After the signal 
transduction initiated by the 
ligation of these PRRs to their 
ligands, there is an increase in 
the expression of pro-
inflammatory cytokines like 
IL-1, IL-6, TNF-α, among 
others, as illustrated in Fig. 4. 
The cytokines, together with 
chemokines, allow the 
recruitment of effector cells 
like neutrophils and 
monocytes to the injured site. 
At this point, the typical symptoms of local inflammation appear: heat, swelling, redness, pain 
and loss of function (Fig. 5). 
If the response is successfully accomplished, the result is the elimination of the 
infectious agent. The resolution phase is characterized by the transition from pro-
inflammatory prostaglandins to anti-inflammatory lipoxins that will inhibit the recruitment of 
Figure 5: Effectors of inflammation. Neutrophils and monocytes 
migrate to damaged tissue, followed by protein rich fluid (exudate) that 
promotes swelling. Mast cells and tissue-resident macrophages promotes 
this migration through the release of histamine, prostaglandins and 
leukotrienes causing vasodilatation and an increase in vascular 
permeability. Adapted from Ashley et al [18]. 
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neutrophils and bring monocytes to the hound, for dead cells removal, and promotion of 
tissue remodeling [18]. 
 
1.3.3. RIG-I-like receptors 
 
Retinoic acid-inducible gene I (RIG) like receptors (RLRs) are cytoplasmic RNA 
helicases expressed in almost all cells and that detect viral RNA in the cytoplasm of infected 
cells, resulting in inflammation. However, besides RNA, they can act against viral DNA and 
bacterial pathogens. The signaling pathway triggered leads to the transcription and induction 
of interferon-mediated antiviral responses, recruiting immune cells like macrophages and 
dendritic cells. Ultimately, the triggering of these receptors will originate apoptosis in infected 
cells, up-regulation of MHC class I and enhanced adaptive immune responses [24]. 
 
1.3.4. C-type lectins 
 
C-type lectins are soluble or transmembrane receptors, capable of recognizing a wide 
range of molecules like carbohydrates, lipids and proteins. The carbohydrate recognition 
domain, with conserved motifs, enables carbohydrate specificity, allowing the recognition of 
viruses, bacteria or fungi. The pathway is complex and requires interaction with other PRRs to 
induce the phagocytosis of pathogens by dendritic cells and subsequent antigen presentation. 
Dectin-1 belongs to this family and is a type 2 transmembrane protein expressed by DC, 
monocytes, Mɸs and neutrophils. They act as antifungal defenses and may recognize Listeria 
and Mycobacterium  [25]. 
 
1.3.5. Scavenger receptors 
 
Scavenger receptors (SR) are a large family of structurally heterogeneous, 
transmembrane and cell-surface glycoproteins. They may contain in their structure collagen, 
C-type lectins, or scavenger receptor cysteine-rich (SRCR) domains, among others. SR can 
recognize different ligands from non-self to altered self-targets promoting the removal 
thereof. This is accomplished by endocytosis, phagocytosis, adhesion and signaling 
mechanisms. They were first described as receptors with the ability to uptake low density 
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lipoproteins (LDL) in macrophages, then several proteins have been classified as SR and new 
properties were discovered, for example as being involved in phagocytosis, antigen 
presentation, and clearance of apoptotic cells [26]. The nomenclature applied to scavengers 
receptors was type I and II macrophage scavenger receptors. As new receptors were 
discovered, the nomenclature changed to class A scavenger receptors I and II. Currently this 
large family is divided in ten classes (SR A-J) [27]. These receptors have an important role in 
innate immunity and the association of SR to pathogens and modified lipids implicates these 
proteins in inflammation and metabolic disorders.  
As previously mentioned, the inflammatory process may lead to chronic inflammatory 
or autoimmune diseases when mediators that initiate and maintain inflammation and those 
promoting the resolution of inflammation are not well coordinated. An example of such 
imbalance is atherosclerosis, a disease where some SR play an important role, that results from 
the accumulation of lipids and fibrous elements in large arteries. Lipoproteins detained in the 
subendothelial space may go through modifications inducing an activation of the immune 
response. Monocytes are then recruited to the subendothelial space, differentiate into 
macrophages enabling the phagocytosis of the modified lipoproteins mediated by the SR 
CD36, together with Spα (further detailed in the section 3) promoting the transformation into 
foam cells. These cells secrete substances that are involved in plaque growth, leading to 
disease progression [28]. Multiple sclerosis (MS) is another inflammatory disease where a SR is 
involved. This chronic autoimmune disease results from a deregulation of inflammation in the 
myelinated axons of the central nervous system, ultimately leading to neurodegeneration. 
Recently it was found that a single nucleotide polymorphism in CD6, a member of the SR 
family, is associated with a lower risk for multiple sclerosis. CD6 has a ligand named 
CD166/ALCAM (leukocyte cell adhesion molecule) located in the epithelial layer of the 
blood-brain barrier (BBB) and when both molecules interact, allows the passage of CD4+ T 
cell through the BBB. Therefore, a reduction in the ALCAM-CD6 interaction that can occur 
through increased skipping of the ALCAM-binding domain in CD6 may reduce the 
transmigration of T lymphocytes through the BBB protecting against MS [29]. 
Besides inflammatory diseases, SR may have a role in macrophage polarization too, as 
is the case of CD163, CD36 and SR-A1 that have their expression increased in M2 
macrophages. SR-A1 and CD36 contribute to M2 macrophages clearance of apoptotic bodies 
and CD163 promotes an anti-inflammatory response [26]. 
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2. Scavenger receptors cysteine-rich superfamily 
 
The scavenger receptors cysteine-rich (SRCR) superfamily is characterized by proteins 
containing scavenger domains composed of about 100 amino acids having the cysteine residue 
positions highly conserved among species, already found in echinoderms, sponges, mammals, 
fish, avian and amphibian. The proteins of this family can be expressed in diverse types of cell 
and can be secreted or be cell surface bound mediating protein-protein interactions and ligand 
binding. SRCR proteins are involved in diverse functions such as pathogen recognition, 
modulation of immune responses, epithelial homeostasis and tumor development, among 
others. There are two groups in this superfamily, group A and group B. These two groups 
differ from one another in the number of exons that encode the scavenger domains and in the 
number of cysteines present in each domain. The members of SRCR A have their SRCR 
domains encoded by split exons and possess eight cysteine residues. On the other hand, SRCR 
B domains are encoded by a single exon and have six cysteine residues [30]. 
Different proteins from SRCR B have been described as having diverse functions; 
however there is no feature that unifies them, except for the structural properties of the highly 
conserved domains. Some of these proteins seem to be related to the innate and the adaptive 
immune systems. It was reported that members of this family are capable of detecting PAMPs, 
thus acting like PRRs [31]. For instance, deleted in malignant brain tumor 1 (DMBT1) is a 
glycoprotein that has 14 SRCR domains and plays a role in the interaction between tumor cells 
and the immune system. DMBT1 can be secreted or associated with the plasma membrane of 
macrophages, but can also be found in other types of cells, predominantly in epithelial-like 
tissue. It was reported that DMBT1 levels are higher on fetus than in the adult and the 
location of this protein varies according to the developmental stage. This protein also plays a 
role in virus and bacteria elimination, since it can bind, agglutinate and neutralize them, 
protecting the epithelial and mucosal tissues [32].  
CD5 and CD6 are found at the surface of T lymphocytes and are important for the 
modulation of activation of these cells. Both molecules are membrane glycoproteins and have 
3 extracellular SRCR domains, a transmembrane region and cytoplasmic tail for intracellular 
signal transduction. They have the ability to bind to conserved PAMPs from bacteria and 
fungi. CD6 can aggregate bacteria in a way to prevent its transversion through the epithelial 
barrier [4]. Transmembrane glycoprotein CD163 with 9 SRCR domains is exclusively 
expressed on monocytes and macrophages and act as an innate sensor against bacteria. Its 
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expression is upregulated by anti-inflammatory inducers (glucocorticoids, IL-10) and 
downregulated by pro-inflammatory agents (LPS, TNF-α). It also has a role in iron 
metabolism since this protein can bind to hemoglobin-haptoglobin (Hb-Hp) complexes 
leading to hemoglobin removal from plasma. CD163 has a soluble form circulating in the 
plasma resulting from the shedding of the ectodomain [33]. SSc5D is composed of five SRCR 
domains and is another member of this family for which very little is known. The SSc5D 
mRNA is abundant in monocytes, macrophages, T lineage cells and placenta, but not in B 
lymphocytes. These proteins and others not listed are found in human cells and are 
schematized in Fig. 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both Spα (secreted protein alpha) and S4D-SRCRB (soluble protein with 4 domains 
SRCR) belong to SRCR B group [34] and are the subject of this work being more detailed in 
the next sections. 
Figure 6: Representation of human SRCR B members. Their structure is composed of single or tandem 
repeats of SRCR domains and some are mosaic or multidomain proteins, providing variability.  
 
The structures are: 
CUB-C1r/C1s Uegf Bmp1 domain; 
PST- proline-, serine-, and threonine-rich sequence; 
ZP - zona pellucida domain. 
Figure adapted from Martínez et al [4]. 
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3. The Spα protein 
 
Secreted protein alpha (also known as Api6 or CD5L) was first described in 1997 [35]. 
This human soluble glycoprotein (38 kDa) is not membrane bound and has a secretory signal 
sequence followed by three SRCR domains. The authors reported that Spα transcripts were 
restricted to lymphoid tissue (spleen, lymph nodes, thymus, bone marrow) but it could bind to 
resting myeloid cells and peripheral blood monocytes, suggesting that this protein may play a 
role in the regulation of the immune system. By contrast, the protein is not found in 
peripheral blood lymphocytes (PBL), appendix, prostate, testis, uterus, small intestine and 
colon [35]. Later it was found that it is an abundant circulating serum protein that is associated 
with other serum components like IgM [36]. 
Multiple roles for Spα were described and its role in inflammation is somehow 
confusing by the different reports showing that depending on the model studied, this protein 
can behave as a pro- or anti-inflammatory molecule (fig.7) [37]. 
Spα was described as a PRR because it could bind to LPS and LTA and also to a 
variety of Gram-positive and Gram-negative bacteria in a dose-dependent way [38]. 
It is a novel serum biomarker for liver fibrosis in hepatitis C [39] and for atopic 
dermatitis, since its presence in serum increases in these patients [40]. Furthermore, the 
increased expression of Spα may lead to lung inflammation and it can control epithelial 
cancerous transformation and myeloid cell proliferation by inhibiting apoptosis and activating 
oncogenic pathways in a lung adenocarcinoma context [41]. Recently it was demonstrated that 
Spα activates autophagy in Mɸs through the modulation of CD36 expression, thereby 
downregulating their inflammatory status by preventing the secretion of TNF and IL-1β 
(derived from the TLR pathway) and increasing the production of IL-10 [42]. 
AIM (apoptosis inhibitor expressed by macrophages) is the homologous protein of 
Spα in mice, sharing 70% similarity. This homologue is only expressed by tissue macrophages 
and appears to increase resistance to apoptosis suggesting an important role in inflammatory 
and infection sites [43, 44]. AIM was broadly studied in the last decade, being a model to the 
human Spα protein. In combination with TGF-β, this protein inhibits B lymphocyte 
proliferation induced by LPS stimulation [45]. 
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AIM is being related to metabolic disorders such as atherosclerosis and obesity. In an 
atherosclerosis condition, monocytes migrate into the subendothelial space of blood vessel 
and differentiate into Mɸs. In hyperlipidemic conditions, Mɸs incorporate oxLDL via CD36. 
oxLDL causes cytotoxic effects that leads to apoptosis. AIM present in Mɸs promotes its 
survival against the apoptotic signals and Mɸs with oxLDL increase the expression of AIM. 
Ultimately, these effects cause the characteristic atherosclerotic lesions. Knockout mice for 
Figure 7: Different features of Spα in inflammation.  
This protein may influence macrophage response in atherosclerosis, survival against bacteria and TLR response. 
Besides that, it promotes recruitment of leukocytes, Ag presentation and in adipocytes contributes for lipid 
uptake. In epithelial cells is associated to cancer in liver and lung. Adapted from Sanjurju et al [37]. 
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AIM showed that these lesions are markedly decreased when compared with control AIM+/+ 
mice, thereby demonstrating the role of AIM in this pathology [37, 46].  
Another role for AIM in metabolic-associated disorders is given by a distinct report 
showing that soluble AIM is endocytosed into adipocytes via CD36 and within these cells, 
AIM associates with cytosolic fatty acid synthase (FAS), thereby decreasing FAS activity. This 
decreases lipid droplet size and prevents adipocyte maturation, suggesting that AIM 
specifically influences adipocyte status. Thus, this AIM function in adipocytes may be 
physiologically relevant to obesity progression [47]. 
The anti-apoptotic protein is also involved in the immune response against infection. 
Indeed, it was demonstrated that AIM contributes to autophagy mechanisms and participates 
in the vitamin D antimicrobial pathway in the response of macrophages to Mycobacterium 
tuberculosis. Furthermore, the expression of AIM in THP-1 cells renders them resistant to 
apoptosis induced by M. tuberculosis infection [48]. This protein is also a PRR for PAMPs from 
bacteria and fungi and besides mediating this recognition, AIM may reduce pro-inflammatory 
cytokines and chemokines secretion, benefiting the tissue protection against responses elicited 
by PAMPs [49]. 
 
4. The S4D-SRCRB protein 
 
Although structurally similar to Spα, very little is known about the expression pattern 
and localization of S4D-SRCRB. This protein is composed of four SRCR domains with short 
proline-serine-threonine (PST) rich polypeptides between them. Its mRNA expression was 
analyzed in human tissues by Northern blotting and a wide distribution of S4D-SRCRB was 
observed in various tissues and cell lines of different origins: kidney, placenta, peripheral 
blood lymphocytes, small intestine, liver, spleen, colon, skeletal muscle, heart, brain, fetal liver 
and bone marrow. S4D-SRCRB mRNA has two major forms, one with 1.5 kb with a large 
distribution in different cell lines (HeLa, A549, HEp2, HEK 293T) and another with 2.8 kb 
with a more restricted distribution, being present only in HepG2 cell line. In order to correlate 
the S4D-SRCRB expression with the inflammatory context of cells, the expression of this 
protein was analyzed upon stimulation with the pro-inflammatory cytokines IL-1 and IL-6 or 
dexamethasone. However no change in the S4D-SRCRB mRNA levels was observed [50]. 
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5. Objectives 
 
The characterization of both Spα and S4D-SRCRB proteins is important to 
understand theirs contribution in immune responses. While the role(s) of S4D-SRCRB remain 
largely unknown, the importance of Spα as a PRR and its involvement in inflammation was 
already observed. Nonetheless, numerous mechanisms associated with these proteins remain 
unexplored. 
With this work it is intended to unveil the functions of these proteins. In order to 
achieve this goal, the first step was to analyze the expression of these proteins in different 
human cell lines and tissues by mRNA, immunohistochemistry and western blotting. Cell lines 
and some primary cells were the first approach due to their availability and ease of use. To 
understand the dynamics of protein production and secretion depending on the inflammatory 
context, different stimuli and kinetics were employed to analyze changes in the tested protein 
levels.  
The second part of the work is to identify possible ligands for Spα and S4D-SRCRB. 
For this purpose the recombinant proteins were produced and purified and binding assays to 
different human cell lines were then performed. 
Following this path, hopefully the expectation is to find a clue about the function of 
these proteins and their role as pro- or anti-inflammatory molecules. 
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II. MATERIAL AND METHODS 
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1. Cell line culture 
 
Epithelial cell lines used in this work were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% fetal bovine serum (FBS) from Gibco, 1% penicillin and 
streptomycin (Gibco) corresponding to complete media, at 37 ºC and 5% CO2. 
Hematopoietic-origin cell lines were grown in complete Roswell Park Memorial Institute 
(RPMI) media from Gibco also with the same components as described for DMEM. Each cell 
line was split when approaching approximately 90% confluence. 
All cell lines were acquired from the American Type Culture Collection (ATCC). 
 
2. SDS-PAGE and western blotting 
 
Cell lysates were prepared by lysing 3 x 106 cells with lysis buffer (Triton X-100) for 45 
minutes (min) on ice. Samples were centrifuged at 13,000 x g for 10 min at 4 ºC and the 
protein content from the supernatant was quantified by Bradford Assay (BioRad). 60 μg of 
each lysate was mixed to 6x Laemmli Sample buffer, denatured for 5 min at 95 ºC and loaded 
on a 10% SDS-polyacrylamide gel (SDS-PAGE) and separated for 45 min at 200 V.  Samples 
were transferred to a nitrocellulose membrane (iBlot). The membrane was blocked with a 
solution of 5% non-fat milk in Tris-Buffered Saline and 1% Tween (TBS-T) for 1 hour at 
room temperature (RT), then incubated with the primary antibody in a solution of 3% non-fat 
milk in TBS-T overnight at 4 ºC. The membrane was washed 3x with TBS-T during 10 min 
and subjected to the HRP-conjugated secondary antibody in a solution of 3% non-fat milk in 
TBS-T during 1h at RT. ECL solution (GE Healthcare) was used to develop a 
chemiluminescent signal in an X-ray film (GE Healthcare) or using a digital acquisition devise 
(ChemiDoc, Bio-Rad). First and second antibodies used for protein detection were: mouse 
monoclonal anti-Spα IgG2a (Santa Cruz Biotechnology), mouse monoclonal anti-HA (16B12, 
Abcam), mouse monoclonal anti human α-Tubulin (B-5-1-2, Sigma Aldrich) and goat anti 
mouse IgG-HRP (Sta Cruz Biotechnology). 
 
3. Monocyte isolation and in vitro differentiation and activation of MΦs 
 
Peripheral blood mononuclear cells (PBMCs) were obtained from human peripheral 
blood from healthy volunteers donors from Hospital de São João of Porto. The separation of 
24 
 
blood constituents was performed by density gradient centrifugation using Lympholyte®-H 
(Cedarlane). To eliminate erythrocytes, PBMCs were subjected to red blood cells lysis buffer 
and further washed with phosphate buffered saline (PBS, HyClone) to reduce platelet 
contamination. Cells were counted and seeded in a culture flask for monocytes to adhere for 
40 min. The supernatant was removed and cells were tripsinized. A part of the monocytes 
were lysed as already described for western blotting (WB) and the other part was plated into a 
6 well plate at a density of 0.5 x 106/mL in RPMI complete medium. To differentiate these 
cells into macrophages, GM-CSF (for a type 1 MΦs) was added to a final concentration of 20 
ng/mL, or M-CSF (for a type 2 MΦs) at a final concentration of 50 ng/mL. Cells were 
incubated at 37 ºC, 5% CO2 for 7 days (after 3-4 days of culture, new complete medium 
supplemented with GM-CSF or M-CSF was added to the culture). After 7 days, cells were 
used to extract total RNA. 
 
4. Total RNA extraction and PCR 
 
4.1. Total RNA extraction 
 
Different cell lines and GM-CSF/M-CSF differentiated MΦs were incubated with 
TripleXtractor reagent (Grisp) at room temperature (RT) for 5 min to allow complete 
dissociation of nucleoprotein complexes. Isolation of total RNA was performed according to 
the manufacturer’s instructions. Per 1 mL TripleXtractor was used 0.2 mL chloroform and the 
tubes were shacked vigorously for 15 seconds and incubated at RT for 3 min. After a 
centrifugation of 12,000 x g for 15 min the colorless part of the sample containing the RNA 
was transferred to a new RNase-free tube and 0.7 volumes of ethanol were added to a final 
concentration of 35%. Samples were transferred to a RNA mini spin column from the RNA 
Extraction kit (Grisp) and the manufacturer protocol was followed. Quantification was 
performed in a NanoDropTM 1000 Spectrophotometer and 5 μg were collected to perform 
first-strand cDNA synthesis. RNA was stored at -80 ºC. 
 
4.2. First-strand cDNA synthesis 
 
Following manufacturer’s procedures for first-strand cDNA synthesis, 5 μg of RNA 
were incubated with 1 µL of random primers, 1 µL of dNTPs (10 mM) and nuclease free 
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water to make up to 13 µL for 5 min at 65 ºC followed by incubation on ice for 1 min. A 
mixture of 4 µL 5x First-Strand buffer, 1 µL of DTT (0.1 M), 1 µL RNaseOUTTM 
Recombinant RNase Inhibitor and 1 µL of SuperScriptTM III Reverse Transcription (200 
units/µL) (Invitrogen) was added to the sample. Samples were incubated at 25 ºC for 5 min 
and then at 50 ºC for 60 min. Following reverse transcription, cDNA was stored at -20 ºC or 
used in a Polymerase Chain Reaction (PCR). 
 
4.3. PCR amplification 
 
For PCR amplification, a master mix containing 1.25 µL of forward primer and the 
same for reverse primer (table 1), 5 µL GoTaq® Flexi Buffer (Promega), 5 µL of MgCl2, 1 µL 
DMSO, 1 µL of dNTPs, 0.15 µL GoTaq® DNA Polymerase (Promega) and 8.35 µL of 
nuclease free water for a final volume of 23 µL was prepared. To this mixture, 2 µL of cDNA 
was added. An optimized program for PCR was used starting with initial denaturation lasting 5 
min at 95 ºC and followed by 35 cycles: 30 sec at 95 ºC (denaturation), 30 sec at 65 ºC 
(annealing) and 40 sec at 72 ºC (extension). The final extension took 5 min at 72 ºC. As 
control, a PCR reaction of the same samples with β-actin primers (0.5 µL) was also performed. 
Samples obtained from PCR were analyzed by gel electrophoresis in a 1% agarose gel. 
 
 
Table 1: Oligonucleotides and the respective sequences used in each PCR. 
Oligonucleotide Sequences 
S4D-PCR-F 5’ GGCGTCCACAATTGCTTTCA 
S4D-R3 5’ ACGGATCTGTCTGCCAAG 
S4D-MIuI-F 5’ TAGACGCGTATGCACAAGGAAGCAGAGA 
S4D-cBamHI-R 5’CTAGGATCCCGAGCGTAGTCTGGGACGTCGTATGGGTATGA
AGGCTGGCACAGGACACT 
M13-F 5’ CCCAGTCACGACGTTGTAAAACG 
M13-R 5’  AGCGGATAACAATTTCACACAGGAA 
SFFV-F 5’ TGCTTCTCGCTTCTGTTCG 
Citrine-R 5’ GCTGAACTTGTGGCCGTTTA 
actB-F 5’  TGATGGTGGGCATGGGTCAGA 
actB-R 5’  AATGTCACGCACGATTTCCCG 
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5. Over expression of S4D-SRCRB protein in Caco-2 and Jurkat E6.1 cells 
 
5.1. Cloning, transformation and plasmid preparation 
 
Since S4D-SRCRB RNA is expressed in the HepG2 cell line, this was selected to 
perform a PCR reaction for cDNA amplification. The master mix contained 1.25 µL of 
forward primer and the same for reverse primer (table 1), 4 µL 5x Phusion Buffer (Thermo 
Scientific), 0.6 µL DMSO, 0.4 µL of 10 mM dNTPs, 0.2 µL Phusion DNA Polymerase 
(Thermo Scientific) and 16.3 µL of nuclease free water for a final volume of 24 µL was 
prepared. To this mixture, 1 µL of cDNA was added. An optimized program for PCR was 
used starting with initial denaturation lasting 30 sec at 98 ºC and followed by 35 cycles: 15 sec 
at 98 ºC (denaturation), 20 sec at 68 ºC (annealing) and 50 sec at 72 ºC (extension). The final 
extension took 10 min at 72 ºC. 
The final product of PCR was analyzed in a 1% agarose gel and the band of interest 
was cut followed by DNA purification using a GRS PCR & Gel Band Purification Kit (Grisp). 
The purified gel band (5 µL) was incubated with 0.5 µL of TOPO® cloning vector and 0.5 µL 
of saline solution for 30 min RT. The mixture was transformed in TOP10 chemically 
competent E. coli by mixing 50 µL of cells with the sample. The preparation was incubated on 
ice for 30 min and heat shocked at 42 ºC for 60 sec and transferred to ice for 2 min. LB 
medium (500 µL) was added to the sample and incubated for 1 h at 37 ºC. Bacterial cells were 
then plated on LB agar containing 100 µg/µL of ampicillin and 50 µg/mL of XGal and grown 
at 37 ºC overnight. 
 
5.2. Colony PCR 
 
Using colony PCR analysis, 15 colonies were chosen for confirmation of E. coli 
transformation. A master mix mixture was made using 1 µL of each primer (M13R and 
M13F), 0.4 µL of dNTPs, 2 µL GoTaq® Flexi Buffer (Promega), 2 µL of MgCl2, 0.4 µL 
DMSO, 0.06 µL GoTaq® DNA Polymerase (Promega) and 3.14 µL of nuclease free water for 
a final volume of 10 µL. An optimized program for PCR was used starting with initial 
denaturation lasting 5 min at 95 ºC and followed by 35 cycles: 30 sec at 95 ºC, 30 sec at 55 ºC 
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and 2 min at 72 ºC. The final extension took 5 min at 72 ºC. Final colony PCR products were 
analyzed in a 1% agarose gel. 
Two positive colonies were inoculated in 5 mL of LB medium supplemented with 100 
µg/mL of ampicillin and grown overnight at 37 ºC in an orbital incubator. Using GRS 
Plasmid Purification Kit from Grisp, mini-preps of these clones were made according to the 
manufacturer’s procedure. Plasmid DNA was quantified using a NanoDropTM 1000 
Spectrophotometer and sent for sequencing. 
After obtaining the results from sequencing, plasmid DNA from a positive colony was 
digested with MluI and BamHI enzymes for 2 h at 37 ºC. The pHR-mCitrine vector was also 
digested with the same enzymes. A ligation protocol was performed for the S4D-SRCRB 
insert and pHR vector using T4 DNA Ligase (Fermentas) for 1 h at 22 ºC followed by 
transformation in TOP10 competent E. coli as described above. A new colony PCR was 
performed identically to the already described but with different primers: SFFV-F and 
mCitrine-R. Positive colonies were grown and plasmid was purified as describe above. The 
final sample was sent for sequencing. 
 
5.3. Stable transfection 
 
HEK 293T cells were counted and plated on 6 well plate at a concentration of 3 x 105 
cell/mL in 2 mL of DMEM media and incubated overnight. Cells were transfected using 4.5 
µL Lipofectamine® 2000 reagent (Invitrogen) and 100 µL of minimal essential medium (Opti-
MEM, without supplements) with a mixture of 0.5 µg of three vectors needed for virus 
assembly (p8.91, pMD-G and pHR-citrine S4D-SRCRB). The mixture was incubated for 30 
min at RT and added to HEK 293T cells. Cells were incubated for 48-72 h at 37 ºC to allow 
virus assembly and production into the supernatant. For stable over expression of S4D-
SRCRB protein by lentiviral transduction, Caco-2 (epithelial like) and Jurkat E 6.1 
(lymphoblast) cells were chosen. Caco-2 were counted (5 x 105 cells) and plated the day before 
transduction and Jurkat cells were plated in the same day of the transduction (1 x 106 cells).  
The supernatant from HEK 293T was filtered and added to Caco-2 and Jurkat cells followed 
by incubation at 37 ºC for 48 h. 
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5.4. FACS analysis for transduction efficiency monitoring  
 
To access the lentiviral transduction efficiency, mCitrine fluorescence was used to 
measure the level of expression of S4D-SRCRB protein in the two cells by flow cytometry. 5 x 
105 cells were washed with FACS buffer (PBS, 0.1% bovine serum albumin and 0.5% sodium 
azide) and filtered before flow cytometer analysis (FACSCalibur). Untransduced cells and cells 
transduced with pHR-mCitrine (empty) were used as controls. Cells were sorted (FACSAria) 
to obtain a homogenous population. Results were analyzed with FlowJo (version VX.0.7.). 
 
6. Stimulation assays in THP-1 MΦs for Spα expression assessment 
 
Monocytic THP-1 cells (1 x 106 cells/mL) were seeded in a 6-well plate with 2 mL of 
RPMI complete media and 10 ng/mL of PMA (phorbol 12-myristate 13-acetate), for 
differentiation of monocytes into macrophages, and incubated at 37 ºC and 5% CO2 for 36 h, 
followed by media replacement to fresh media without PMA for 24 h. Cell were stimulated for 
24 h with LPS (10 ng/mL and 1 µg/mL), IL-10 (10 ng/mL) and dexamethasone (DEX, 100 
ng/mL) or left untreated. Cells were lysed and WB was performed to check for variation of 
Spα intracellular protein upon the different stimuli. 
 
7. Activation of T cells 
 
Jurkat E6.1 cells were subjected to different types of activation in a 6-well plate. 
Activation with αCD3/αCD28 required αCD3 antibody (OKT3 clone, ExBio) coating (5 
µg/mL in 500 µL) and incubation overnight at 4 ºC the day before cell seeding. 1.5 x 106 cells 
were plated in 1.5 mL and αCD28 antibody (CD28.2, BioLegend®) was added in a final 
concentration of 2 µg/mL. Alternative stimulations were achieved using PMA+Ionomycin (10 
ng/mL and 500 ng/mL, respectively) or PHA (phytohemagglutinin, 5 µg/mL), or left 
untreated. T cells were incubated for 6 h for Jurkat E6.1 S4D-SRCRB and 12/24/48 h for Spα 
analysis at 37 ºC with 5% CO2. 
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8. Immunohistochemistry assay 
 
The immunohistochemistry technique used was based on the basic mechanism of the 
binding between the antibody to an antigen by an indirect method. Histological tissue was 
deparaffinized and hydrated with a series of alcohols in decreasing concentration followed by 
antigenic recovery using sodium citrate buffer (10mM sodium citrate, 0.05% Tween 10, pH 6) 
for 30 min at 95-100 ºC. After cooling, the biologic material was submitted to a series of 
treatments according to the manufacturer’s procedure (Thermo Scientific). First, inhibition of 
endogenous peroxidases was performed to avoid non-specific reaction from the chromogen 
agent (DAB – tetra-hydrochloride 3-3’-diaminobenzidin). A new incubation was done with 
Ultra V Block for 5 min at RT. For the assessment of S4D-SRCRB protein presence in tissues, 
slides were incubated with a monoclonal mouse anti-S4D-SRCRB antibody (Santa Cruz 
Biotechnology) (1:50 in PBS) for 1 h at RT. Sections were submitted to the Value Primary AB 
Enhancer then to Value HRP Polymer protected from light. For the development, a mixture 
of DAB Plus Chromogen to DAB Plus Substrate was applied to the slides for 5-15 min. After 
washing with water, counterstain with hematoxilin was performed. After washing, histologic 
sections were dehydrated with a series of alcohols in a crescent concentration and diaphanized 
with xilol. Slides were finally mounted using Vectashield (Vector). For each tissue, a negative 
control with an irrelevant antibody was also performed. 
 
9. Immunofluorescence staining 
 
Slides were placed in a 12-well plate for coating with fibronectin (Sigma-Aldrich) for 1 
h followed by seeding of 1.5 x 105 cells/mL (Caco-2 and Jurkat E6.1 S4D-SRCRB). Cells were 
left to adhere overnight. For immunofluorescence staining, slides were fixed with PFA (4%) 
and blocked using PBS+0.5% BSA. Phalloidin-TexasRed (Molecular Probes, Life Tech) was 
used for F-actin staining and DAPI (Molecular Probes, Life Tech) for nucleus staining. 
Lamellae were mounted using Vectashield (Vector). Samples were observed in a fluorescence 
microscope (Axio imager Z1, Zeiss) for citrine visualization. 
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10. Infection of Caco-2 S4D-SRCRB cells 
 
10.1. Bacterial preparation 
 
Bacterial strains E. coli RS218 (a kind gift from Patrick Trieu-Cuot, Institut Pasteur, 
Paris) and Listeria monocytogenes EGD-e (kindly provided by Didier Cabanes, IBMC, Porto) 
were grown from −80 °C freezer stocks for each experiment and never passaged for longer 
than 48 h prior to infection experiments. Escherichia coli were grown on Luria-Bertani (LB)-agar 
plates while Listeria monocytogenes were grown in brain heart infusion (BHI)-agar plates and 
incubated at 37 °C. One colony of each bacterial strain was inoculated into liquid LB (BD, 
Fisher Scientific) for E. coli or BHI media (BD, Fisher Scientific) for L. monocytogenes. Cultures 
were grown on a shaking incubator at 37 °C overnight. The bacterial cultures were diluted into 
fresh bacterial medium and grown, as previously described, until the exponential phase (OD600 
≅ 0.3-0.4). 
Bacteria were harvested by centrifugation at 4000 x g for 10 min at 4 ºC and washed 
three times in PBS. Samples were diluted in PBS to obtain an OD of 0.45 (corresponding to 
2.5 x 108 colony forming units (CFU)/mL). Bacteria were then diluted in DMEM without FBS 
or antibiotics for the appropriate multiplicity of infection (MOI). Quantification of CFU was 
done by serial dilutions and plating bacteria in LB and BHI agar plates. 
 
10.2. Infection assays 
 
3 x 105 Caco-2 cells per well were seeded in a 12-well plate the day before infection. 
Cells were incubated with the bacterial suspensions for 1 h at 37 ºC. After this period, which 
was considered as 0 h, cells were extensively washed with PBS and treated cells were lysed as 
described above. The remaining cells were incubated with fresh DMEM without FBS 
containing 1% penicillin and streptomycin and 0.05% gentamycin (Gibco) for 2 h before lysis.  
Cells were adhered to slides and prepared similarly for immunofluorescence staining 
but without performing cell lysis. 
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11. Protein production and purification 
 
11.1. Histidine-Tagged recombinant protein purification 
 
CHOK1 cells stably expressing recombinant Spα or S4D-SRCRB were cultured in 
complete DMEM supplemented with 2.5% FBS and 1% penicillin and streptomycin in 4-tray 
cell-factories for approximately 30 days at 37 ºC in 5% CO2. Production of recombinant 
proteins was controlled once a week through WB of supernatant samples. 
Supernatant was collected, 0.2 μm filtered and concentrated using a Vivaflow 200 with 
a 10 KDa cut-off (Sartorius) following the manufacturer instructions and dialyzed to binding 
buffer (20 mM sodium phosphate, 150 mM NaCl and 10 mM imidazole, pH 7.4). The 
concentrated supernatant was loaded into a HisTrap HP column (GE Healthcare) in a low-
pressure liquid chromatography system. Washing was performed with buffers containing 
increasing concentrations of imidazole: 20 mM sodium phosphate, 150 mM NaCl and 10 
/20/30/100/250/500 mM imidazole, pH 7.4. Using a BioRad BioLogic Fraction Collector, 
the components trapped in the column were separated and the proteins were purified. 
Fractions were analyzed with BioRad BioLogic LP data view software. Fractions of interest 
were selected for an SDS-PAGE and stained with Blue Safe (NzyTech). Selected samples were 
pooled, dialyzed against HEPES-buffered saline (HBS) (20 mM HEPES, 50 mM NaCl, pH 
7.4) and stored at -80 ºC for posterior use. 
 
11.2. Size exclusion chromatography purification 
 
Recombinant Spα (rSpα) purified by affinity chromatography was subjected to a new 
type of purification for purity optimization using size exclusion chromatography in an AKTA 
Purifier 10 fast protein liquid chromatography high-pressure system (GE Healthcare). Samples 
were injected in a Superose 12 10/300 GL column (GE Healthcare) and flow of HBS was 
allowed to pass through the column for protein elution at pressure < 2.5 MPa using a fraction 
collector Frac 950 (GE Healthcare). Fractions were analyzed with the UNICORN software 
(GE Healthcare). Fractions of interest were selected for an SDS-PAGE and stained with Blue 
Safe (NzyTech). Selected samples were pooled, dialyzed against HEPES-buffered saline (HBS) 
(20 mM HEPES, 50 mM NaCl, pH 7.4) and stored at -80 ºC for posterior use. 
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11.3. Production of recombinant S4D-SRCRB protein by transient transfection 
 
HEK 293T cells were seeded at 3.5 x 106 cells/mL in a petri dish with 8 mL of 
DMEM complete media. Transient transfection was made with PEI (polyethylenimine) using 
an optimized protocol. A mixture of PEI (1:10) and pEE14 S4D-SRCRB vector in opti-MEM 
was incubated at RT for 20 min and added to cells for 3 h at 37 ºC. Media was replaced with a 
fresh one and the culture maintained for approximately 2.5 weeks. After a week, protein 
expression of each petri dish was assessed by collecting a supernatant sample for WB.  
All supernatants from the petri dishes were pooled and purified using a batch 
purification method based on nickel affinity following the manufacturer’s instructions. Briefly, 
the supernatant was added to His-Selected® Nickel Affinity Gel (Sigma-Aldrich®) and gently 
mixed for 30 min in an orbital shaker (175 rpm) at 4 ºC. After centrifugation, the supernatant 
was removed and the gel washed 3 x with an appropriate buffer (50 mM sodium phosphate, 
pH 8, with 0.3 M sodium chloride). Using an elution buffer (50 mM sodium phosphate, pH 8, 
with 0.3 M sodium chloride and 250 mM imidazole) the purified protein was obtained. To 
confirm the purity and the protein yield, an SDS-PAGE was performed followed by Blue Safe 
coloration and WB. 
 
12. Search for ligand binding to rSpα 
 
12.1. Biotinylation of rSpα 
 
An rSpα sample purified by size exclusion chromatography was subjected to buffer 
exchange to 10 mM Tris, pH 8, to a final concentration of 2 mg/mL. A Biotinylation Kit 
(Avidity) was employed for sample biotinylation (according to the manufacturer’s procedures) 
and the mixture was incubated for 2 h at 30 ºC, then left overnight at 4 ºC in an orbital shaker. 
Biotinylation was confirmed using a pull-down assay with streptavidin beads (Sigma-Aldrich) 
and WB using streptavidin-HRP incubation. Protein sample was quantified by Bradford assay 
(Bio-Rad). 
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12.2. Tetramer preparation and binding assays 
 
For tetramer assembly, a solution of molar excess of rSpα (200 µg/mL) was mixed 
with 50 µg/mL streptavidin-A647 (Molecular Probes) in HBS or streptavidin-A647 only, as 
negative control, and incubated in an orbital shaker for 1.5 h at 4 ºC. 2.5 x 105 cells were 
washed and incubated with 30 µL of tetramer mix or control for 45 min on ice. Cells were 
washed 3 x in FACS buffer and 4 µg/mL propidium iodide counterstaining was made for the 
exclusion of dead cells. For the assays in the presence of Ca2+, 0.9 mM CaCl2 was added to the 
HBS and to the FACS buffer during tetramer assembly and cell washes. Cells were then 
analyzed in a flow cytometer (FACS Calibur). Results were analyzed using FlowJo (version 
VX.0.7.). 
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III. RESULTS AND DISCUSSION 
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1. Spα expression 
 
Human Spα (hSpα) mRNA was found to be present in the bone marrow, spleen, 
lymph node, thymus and fetal liver but not in non-lymphoid tissues [35]. However, the 
majority of the characterization of this protein is being performed in the mouse context, 
where it was observed that the main cellular sources of mouse Spα (mSpα) are tissue 
macrophages [43]. However, it has been demonstrated that although similar, mSpα and hSpα 
have differences in their glycosylation patterns. Indeed, while hSpα has no N-glycosylation 
sites, mSpα has 3 sites and this difference may be relevant for the function of the protein since 
mutation in 2 N-glycosylation sites of mSpα affects its secretion while enhances its lypolytic 
activity in adipocytes [51]. 
 In order to elucidate the expression pattern of hSpα at the protein level, a cell line 
screening using human cells from different origins was performed. 
After analyzing the expression of hSpα, experiments with inflammatory and anti-
inflammatory stimuli were made in a chosen cell line demonstrated to express this protein. 
 
1.1. Cell line expression 
 
hSpα is a very abundant protein in the serum (60 µg/mL) circulating in association 
with IgM [36, 52]. Through the use of an anti-human Spα monoclonal antibody, it is possible 
to easily detect this protein in human serum and plasma, in two different sample dilutions 
tested (1:10 and 1:50), as shown in Fig. 8. Analysis of the WB demonstrates the existence of 
two forms of hSpα having distinct molecular masses due to differences in sialic acid content, 
an observation previously reported by Sarrias et al. [36]. 
 
 
 
 
 
 
 
Figure 8: WB for the detection of Spα in human serum and plasma. 
Two different dilutions (1:10 and 1:50) of serum and plasma were 
subjected to WB. As control, the recombinant Spα protein (rSpα) and 
supernatant from cells over expressing it (SN-Spα) were used. 
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A WB of total lysates of different cell lines and primary cells was performed to assess 
potential tissues where hSpα could be expressed. All the cell lines used and their origin is 
detailed in Table 2. The results obtained indicated that Spα is expressed in epithelial cells 
(HeLa, HEK 293T, JEG-3, Caco-2, HCT 116, MDA-MB-231), lymphoblast (Jurkat E 6.1, 
K562), monocytic (THP-1) and in primary monocytes (Fig. 9). However, the protein levels 
were very low or undetected in HepG2 and TCCSUP cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2:  Origin of each cell line used in the WB analysis of Spα expression. 
The characteristics of the cell lines like morphology and tissue origin are detailed. 
Morphology Cell line Tissue origin 
Epithelial 
HeLa Cervix 
HepG2 Liver 
HEK 293T Human embryonic kidney 
Caco-2 
Colon 
HCT116 
JEG-3 Placenta 
TCCSUP Unary bladder 
MDA-MB-231 Mammary gland 
Lymphoblast 
K562 Bone marrow 
Jurkat E 6.1 T lymphocyte 
Monocytic THP-1 Monocyte 
Figure 9: Spα expression in different total cell lysates. WB of lysates from each cell line detected with anti-
Spα mouse monoclonal antibody. As loading control, detection of tubulin was also performed. The figure 
reflects one representative assay of multiple experiences made. 
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Although a previous report has showed that the mRNA for Spα was only present in 
lymphoid organs being undetectable in peripheral blood leukocytes and in several cell lines like 
HL60, Raji, Molt4, A549, SW480, GA361, K562 and HeLa [35], this may not be conclusive at 
the protein level. In fact, our observations show that the abundance of transcripts of several 
members of the SRCR superfamily does not relate with protein expression since the mRNA 
coding for these proteins is almost undetectable or is present at very low levels. This fact 
could explain the discrepancy between the reports that point to a unique expression of Spα in 
macrophages and our study showing that this protein is expressed in cells from different 
origins, particularly in epithelial cells. Our observations thus suggest that Spα may have a role 
in different cellular locations or even a different, previously unknown function according to 
the expression site. 
 
1.2. Expression of Spα in response to inflammatory and anti-inflammatory stimuli 
 
Since Spα expression is found in monocytes and these are key mediators of innate 
immune responses, the variation in the expression of this protein upon stimulation was 
performed in THP-1 monocytes. Although our initial screenings were performed using 
different stimuli (LPS, LTA, GM-CSF, M-CSF, IFN-γ, IL-4, IL-10, IL13, TGF-β, TNF-α and 
dexamethasone), here are presented the observations for three of them that gave more 
consistent results in the various experiments made. 
THP-1 cells were firstly differentiated into Mɸs with phorbol myristate acetate (PMA, 
10 ng/mL). This model is widely used since PMA can activate protein kinase C in monocytes, 
mimicking the physiological activator diacylglycerol resulting in a differentiated phenotype 
characterized by increased adherence, loss of proliferation, phagocytic activity, expression of 
CD11b and CD14, release of ROS and production of TNF-α upon LPS stimulation [53]. 
After differentiation, THP-1 cells were treated for 24 h with LPS (10 ng/mL), IL-10 (10 
ng/mL), dexamethasone (DEX, 100 ng/mL) or were left untreated as control. After this 
period, total cell lysates were obtained for WB analysis of Spα expression (Fig. 10). The results 
obtained show that Spα expression is highly increased with DEX treatment while stimulation 
with LPS induced a more moderate effect. Treatment with IL-10, an anti-inflammatory 
cytokine, leads to a reduction of the intracellular amount of Spα. This reduction could be due 
to degradation of intracellular Spα or increased secretion. To elucidate this question, several 
attempts to detect Spα in the supernatant of treated cells were made. However, the protein 
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was never detected probably due to its low levels, a technical issue that despite our efforts, we 
could not solve yet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We next tested whether a different concentration of LPS had any change in the 
dynamics of production and secretion of Spα. For that, differentiated THP-1 cells were treated 
for 24 h with LPS 10 ng/mL, 1 µg/mL, or left untreated as control. The results obtained 
showed that the stimulation with an increased LPS concentration led to a decrease of Spα 
intracellular amount comparing with the lower dose of 10 ng/mL (Fig. 11). This result can be 
explained by an increased secretion of Spα as a possible result of a more rapid production of 
this protein. In order to clarify this question, kinetic studies using different time points with 
different concentrations of LPS are being performed. A relationship between LPS and Spα is 
suggested by the fact that this protein is capable of binding the endotoxin as well as the 
component of Gram-positive bacteria, lipoteichoic acid (LTA) [38]. Furthermore, studies with 
mSpα show that its expression is up-regulated under inflammatory conditions of infectious 
origin, such as infection with Listeria monocytogenes [54], Corynebacterium parvum [55] or in an 
endotoxin-induced fulminant hepatitis [56]. Therefore, it is conceivable that once the presence 
Figure 10: Spα expression in THP-1 total cell lysates upon stimulation. MΦs derived from THP-1 
monocytes were treated with LPS (10 ng/mL), IL-10 (10 ng/mL), dexamethasone – DEX – (100 ng/mL) for 
24 h or left untreated. A) WB of total cell lysates, representing Spα expression (top blot) and tubulin used as 
loading control (lower blot). B) Relative amount of Spα protein to tubulin upon different stimulation, calculated 
by densitometry analysis of band intensity. The figure reflects one representative assay of multiple experiences 
made. 
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of LPS is detected by the cells, a positive feedback loop can induce the production and release 
of Spα as a defense mechanism designed to help the immune system to eliminate a bacterial 
threat.  
The effect of LPS on the expression of SRCR-B proteins was also described for other 
members of this family. Studies performed with CD163 demonstrated that its expression is 
downregulated in monocytes when cells are subjected to low or high concentrations of LPS 
[57]. In contrast, the expression of secreted protein DMBT1 can be up-regulated by LPS via 
NF-kB. Once in the presence of DMBT1, the LPS interaction with cells inhibits TLR4-
induced NF-kB gene activity, suggesting that this SRCR B protein acts as an anti-inflammatory 
molecule [58]. Therefore, both proteins modify their expression when in contact with LPS and 
they are clearly implicated in stablishing anti-inflammatory conditions. Our observation that 
the endogenous levels of Spα are altered in macrophages subjected to the pro-inflammatory 
stimuli LPS suggests that this molecule can have an anti-inflammatory role in the immune 
reaction against Gram-negative bacteria, probably involving TLR as described for DMBT1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results observed in Fig. 10, suggesting a higher expression of Spα in the presence 
of DEX, led us to study this question in more detail by performing a kinetic study of Spα 
expression intracellularly in the presence of the glucocorticoid. After a 24 h treatment, the 
Figure 11: Comparative intracellular Spα amount in THP-1-derived MΦs upon treatment with LPS. 
MΦs were treated with two different concentrations of LPS (10 ng/mL and 1 µg/mL) for 24 h or left untreated. 
A) WB of total cell lysates, representing Spα expression (top blot) and tubulin used as loading control (lower 
blot). B) Relative amount of Spα protein to tubulin upon LPS treatment, calculated by densitometry analysis of 
band intensity. The figure reflects one representative assay of multiple experiences made. 
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intracellular amount of Spα increases significantly and is in accordance with the results 
depicted in Fig. 10. However, increased treatment times of 48 and 72 h with DEX led to a 
decrease in the intracellular amount of Spα over time, being lower than the untreated control 
cells at 72 h (Fig. 12). These results suggest that upon DEX treatment, an initial accumulation 
of Spα occurs as a result of increased protein expression but prolonged exposure times to the 
drug likely induce Spα secretion, although an intracellular degradation cannot be excluded. 
Dexamethasone is an anti-inflammatory and anti-proliferative glucocorticoid that can suppress 
the expression of pro-inflammatory mediators, but also induces the secretion of anti-
inflammatory cytokines like IL-10 [59]. A similar overexpression induced by DEX treatment 
was previously described for CD163 in macrophages. The authors reported that the increase 
of CD163 expression helps in the internalization of toxic Hb-Hp complexes in a dose 
dependent manner, thus supporting an anti-inflammatory role for this SRCR B protein [60]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Altogether the results obtained suggest that Spα may behave as an immune modulator 
of inflammation, whose expression is enhanced in an inflammatory context like the one 
resulting from an infection, but the protein can also have a synergistic role in a more anti-
inflammatory environment and therefore its secretion is enhanced. 
Figure 12: Kinetics of Spα expression in THP-1-derived MΦs upon treatment with dexamethasone. 
MΦs were treated with DEX for 24, 48, 72 h or left untreated. A) WB of total cell lysates, representing Spα 
expression (top blot) and tubulin used as loading control (lower blot). B) Relative amount of Spα protein to 
tubulin upon DEX treatment, calculated by densitometry analysis of band intensity. The figure reflects one 
representative assay of multiple experiences made. 
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1.3. Activation of T cells and Spα expression 
 
After exploring some dynamics of Spα expression in cells from innate immunity and 
since T cells also express Spα, we next investigated whether this protein also changes in cells 
from adaptive immunity upon activation. The strategy was then to activate Jurkat E 6.1 cells (a 
human T cell line), using three different activators and analyze Spα expression by WB. 
T cell activation through αCD3/αCD28 treatment is the activation procedure that 
better mimics in vitro what happens in vivo. The antibodies will trigger an efficient activation 
due to the clustering of the TCR/CD3 complex and the co-stimulatory signal will be provided 
by the antibody against CD28 that acts as a secondary activation signal, required for full T cell 
activation [61]. Phytohemagglutinin (PHA) can activate T cells by binding to cell membrane 
glycoproteins, for example the TCR-CD3 complex, leading to the clonal proliferation of cells 
[62]. The last stimuli used was a combination of PMA, a protein kinase C activator, and 
ionomycin, a ionophore that opens Ca2+ channels present on the endoplasmic reticulum, an 
important event to the signaling pathway occurring upon activation of T cells. These two 
stimuli combined create a synergistic dynamic, increasing the signaling response in T cells [63]. 
The activation of T cells was confirmed by the analysis of CD69 expression by flow 
cytometry. CD69 is a human transmembrane C-type lectin protein that is a commonly used 
early activation marker of T cells [64]. 
The intracellular amounts of Spα in Jurkat T cells stimulated with αCD3/αCD28 
antibodies decreased after 12 h of stimulation, comparing with the untreated control (Fig. 13). 
However, the intracellular levels of Spα were replenished with increased times of stimulation, 
having observed a higher expression at 24 and 48 h of treatment when comparing with the 
levels obtained after only 12 h of activation. The results suggest that the protein could have 
been rapidly secreted upon activation of cells followed by an increase in its production and 
consequent intracellular accumulation in later times reaching comparable levels to the 
untreated cells. A similar behavior in Spα intracellular levels was observed in T cells activated 
with PHA. A decrease in the levels of the protein was observed 12 h post-activation and these 
remained similarly low at least until 24 h after treatment. An increase in the Spα amount only 
occurred later and at 48 h protein levels were higher than in early times of treatment but 
remained lower than those observed for untreated cells. The activation of T cells with PMA 
and ionomycin resulted in kinetics of Spα expression similar to those observed with the 
αCD3/αCD28 treatment. Thus, a decrease in the intracellular levels of Spα happens after 12 h 
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but its expression increases in the next two time points tested (24 and 48 h), remaining higher 
than the intracellular amounts of untreated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the three types of stimulation, Spα seems to decrease after 12 h, a rapid response 
given by T cells after activation. With increased activation time, in all stimuli tested, the 
intracellular amount of protein increases, which raises the question whether a constant level of 
Spα in these cells is important for the homeostasis. Moreover, with the combination of PMA 
and ionomycin the protein increases to levels above the untreated. Since this type of activation 
Figure 13: Kinetics of intracellular Spα levels in Jurkat T cells upon activation. Jurkat T cells were 
activated with anti-CD3 together with anti CD28, PHA, PMA and ionomycin for 12, 24 and 48 h or left 
untreated. A) Activation of T cells accessed by analysis of CD69 expression by flow cytometry. B) Mean 
fluorescence intensity (MFI) of CD69 staining of the cells over time for each treatment. The MFI of CD69 
staining for each treatment was normalized to the isotype control and divided to the MFI of untreated cells, thus 
obtaining a fold change after treatment. C) WB of total lysates of cells to detect Spa expression (top blot) or 
tubulin as loading control (bottom blot). D) Relative amount of Spα protein to tubulin upon activation 
overtime, calculated by densitometry analysis of band intensity. The figure reflects one representative assay of 
multiple experiences made. 
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acts directly on the intracellular pathway triggered upon T cell activation, it could mean that 
there is also a rapidly activated pathway that leads to the increase in the levels of Spα in the 
cell, suggesting that this pathway and the one elicited through TCR activation could be related. 
Other two members of SRCR B are expressed in T cells, CD5 and CD6 proteins, and 
Spα presents a SRCR domain organization similar to these two proteins [35]. It is well know 
that CD5 and CD6 proteins have an important role in T cell homeostasis. CD5 and CD6 can 
induce inhibitory signals in T cells, leading to a decrease in Ca2+ response and suppression of 
cytokines expression resulting in decreased T cell proliferation, a mechanism that involves a 
downstream pathway of the TCR/CD3 complex [65-67]. Due to the relevance of CD5 and 
CD6 in this type of cells and in the regulation of the immune response and taking into 
account the structural similarity with Spα, new studies with this protein could demonstrate an 
important role for Spα in adaptive immunity. 
 
2. Searching for Spα ligands 
 
Given the relative high abundance of Spα in circulation and its anticipated role as an 
immune modulator, the next objective was to identify possible ligands for Spα that would 
enable to better understand and explore the function of this protein. 
 
2.1. Protein production and purification 
 
Spα production and purification in recombinant forms is the first requirement to fulfill 
this task. The protein was produced from stably Spα expressing CHO-K1 cells, already 
available in the lab. These cells were constructed using the glutamine synthetase (GS)-based 
expression system for eukaryotic cell lines. The Spα cDNA was fused with an HA (N-
terminal) and 6xHis (C-terminal) tags for detection and purification and a BirA recognition 
sequence (C-terminal) for biotinylation mediated by BirA (biotin ligase) enzyme (Fig. 14). Due 
to the presence of an engineered signal peptide (RaduSP) in the expression vector (that 
replaces the endogenous one present in Spα cDNA), the recombinant protein is secreted to 
the cell culture media facilitating its purification. Therefore, after recovery of this supernatant, 
two different purification techniques were performed: first by affinity chromatography 
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through the use of nickel media that binds with high affinity to the 6xHis tag present in Spα 
and secondly by size exclusion chromatography to increase the purity of the obtained protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supernatant collected from transfected CHO-K1 cells consists in several components 
from the cell culture medium and proteins released from normal metabolism of these cells, 
besides the recombinant protein of interest. To obtain the recombinant Spα from this mixture, 
affinity chromatography is the first approach because it is based on the specific biological 
interaction between a ligand (nickel immobilized in the column) and the target protein, Spα, 
contained in the mobile phase (mixture). Upon extensive cycles of washing with increasing 
concentrations of an imidazole containing-buffer to eliminate contaminations that bind non-
specifically to the column matrix, Spα was eluted with a 100 and 250 mM imidazole 
containing-buffers (Fig. 15). After purification, several fractions were analyzed on SDS-PAGE 
to check for the presence and purity of Spα. Since the recombinant Spα did not show the 
degree of purity required, fractions 40-60 were pooled and subjected to a different type of 
purification method. 
Figure 14: Schematic representation of the plasmid used to produce recombinant Spα in CHO-K1 cells. 
The Spα cDNA was fused with an engineered signal peptide (RaduSP) allowing the recombinant protein to be 
secreted to the cell culture media, an HA and 6xHis tags for detection and purification, respectively. The protein 
also has a BirA recognition sequence in the C-terminal for in vitro biotinylation. 
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Size exclusion chromatography is a technique that allows the separation of molecules 
according to their size. The fractions selected to use in this purification have less different 
molecules than the original mixture, which facilitates the recovery of the recombinant protein 
with higher purity. Fig. 16 represents the results obtained after this technique. An SDS-PAGE 
analysis demonstrated that the recombinant protein present in fractions B6-B10 had the 
degree of purity required for the binding assays. 
Figure 15: Affinity chromatography purification of Spα. A) Chromatogram demonstrating the different 
fractions collected during the washing and elution steps. Spα was eluted with a 100 and 250 mM imidazole 
containing-buffers. B) SDS-PAGE containing selected fractions after staining with BlueSafe to check the purity 
of selected fractions. Fractions 42-53 presented in this gel demonstrated the presence of Spα, still with some 
remaining impurities. 
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2.2. Ligand binding assays 
 
Due to the measured normally low dissociation constant (Kd) of the interaction 
between cell surface molecules, it is difficult to detect and identify the ligand for a given 
receptor of interest using affinity methods. In order to increase the sensitivity of binding 
detection of soluble Spα to different cell surfaces, we assembled this protein as tetramers 
containing a fluorescent label. To do this, we performed in vitro biotinylation through the use 
of the enzyme biotin ligase that specifically recognizes the BirA recognition sequence included 
in the C-terminal of recombinant Spα (Fig. 14). The resulting biotinylated Spα was mixed with 
AlexaFluor 647-coupled streptavidin, thereby resulting in a tetramer (Fig. 17). 
 
 
 
 
 
Figure 16: Size exclusion chromatography for rSpα purification. The figure represents the chromatogram 
of fractions obtained during the elution and the SDS-PAGE stained with Blue Safe used to check the purity of 
selected fractions. Fractions from B6 to B10 present the degree of purity required for the binding assays 
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Several cell lines from different origins (epithelial, monocytic and lymphoid lineages) 
were tested for expression of ligands to Spα (Table 3). To do this, cells were incubated with 
fluorescent tetramers composed of Spα, human CD2 or empty, as a negative control, and 
subjected to flow cytometry analysis to assess the fluorescent intensity as a direct measure of 
binding. Human CD2 was used in these experiments as a control since the ligand for this 
molecule, CD58, is well known and characterized.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3:  Origins of each cell line used in the binding assay. The 
characteristics of the cell lines like morphology and tissue origin are detailed. 
Morphology Cell line Tissue origin 
Epithelial 
HEK 293T Human embryonic kidney 
HT-29 
Colon HCT 116 
DLD1 
SNU638 Colon 
HCT116 Stomach 
HeLa Cervix 
HepG2 
Liver 
Hep3b 
SKBR3 
Mammary gland 
MDA-MB-231 
Lymphoblast 
K562 Bone marrow 
Daudi 
B lymphocyte EBV 
Raji 
Molt4 
T lymphocyte Jurkat E 6.1 
PM1 
NK92 Natural killer cell 
Monocytic 
THP-1 
Monocyte 
U937 
Figure 17: Illustration of the assembled Spα into tetramers. After the protein biotinylation step, samples 
were mixed with AlexaFluor 647-coupled streptavidin, containing 4 biotin-binding sites, to obtain fluorescent 
tetramers. 
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The results obtained show that Spα can bind to the epithelial cells HeLa, Hep3B and 
SKBR3 and moderately to HEK 293T, HCT116 and SNU638 (Fig. 18). In addition, binding 
was also observed in cells from hematopoietic origin like K562. Binding was not detected or 
was very low in other epithelial cells included in this screening like HT-29, DLD1, HepG2, 
MDA-MB-231 as well as in the cells from hematopoietic lineage Daudi, Molt4, PM1, NK92, 
EBV and U937. The binding of CD2 tetramers followed the expected pattern according to the 
expression of CD58 described. Given the broad expression of CD58, CD2 tetramers bound 
to the majority of the tested cell lines and fluorescence was not detected in some cells reported 
as not expressing or expressing very low levels of CD58, namely Daudi and Molt4. 
It was previously reported that binding of Spα to Gram-positive and negative bacteria 
is only observed in the presence of Ca2+ [38]. We have therefore tested whether the presence 
of this divalent cation induces any change in the binding ability of Spα to the panel of cell lines 
included in the previous experiment. Using a buffer with CaCl2 during the ligand binding 
assay, we observed that this ion can increase binding between Spα and all the cell lines tested, 
even in the ones that were negative for Spα binding in the absence of Ca2+ (Fig. 18). 
Interestingly, the presence of calcium did not significantly change the binding intensity 
of the control CD2 tetramers to all the cells except for Hep3b, SKBR3, MDA-MB-231, 
DLD1 and SNU638 that had the higher MFI increase in the presence of calcium ions (Fig. 
18). 
These findings complete the preliminary information described for Spα that was 
reported as binding to K562, Raji, Hut78 and THP-1 [35]. 
Ca2+ is an important ion in the homeostasis of cells, regulating a myriad of cellular 
functions, affecting every aspect of the cell’s life. In response to stimulus, Ca2+ can be released 
from internal storages or from the exterior of the cell. For instance, intracellular Ca2+ is 
released when needed through itself or by messengers. Extracellular Ca2+ enters into cells by 
plasma membrane channels in response to membrane depolarization, noxious stimuli, among 
others [68]. The binding of calcium to proteins can drive a modification in conformation and 
charge, important for signal transduction [69].  
DMBT1 is a SRCR member known to be associated with innate immune response in 
the oral cavity. A study made with this protein revealed that in the presence of calcium, there 
are glycosylation (more predominantly O-glycosylation) and conformational changes in SRCR 
domains occurring in the DMBT1 protein [70]. Similarly, binding of calcium to some domains 
of CD163 induces a conformation change in this protein increasing the binding affinity to 
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haptoglobin-hemoglobin complexes [71]. By in silico analysis of the sequence of SRCR 
domains of CD163, the amino acids involved in this binding were identified and confirmed 
through different experiments. Sequence analogy also revealed that other members of the 
SRCR B family have potential calcium binding sites and Spα was no exception. Indeed, such 
binding sites are thought to be present in the SRCR domains 1 and 3 of Spα but experimental 
evidence is still missing [71]. Notwithstanding, these clues can explain our results showing that 
Spα binds more intensely in the presence of Ca2+. 
The results in Fig. 18, although suggesting the presence of one or multiple Spα 
ligand(s) in the tested cell lines, do not necessarily reveal the biochemical nature of this 
unknown molecule(s). Therefore, to confirm that this putative ligand(s) is of protein nature, 
K562 and HTC116 cells (positive for Spα binding) were subjected to a mild treatment with the 
protease trypsin prior to tetramer incubation. The results obtained show a decrease in the 
binding of Spα to both cell lines after treatment with trypsin confirming that the ligand(s) for 
Spα is a protein expressed on the cell surface (Fig. 19). There is still some binding of Spα 
tetramers to the cells because the trypsin treatment was moderate to prevent cell death but 
effective as can be observed through the reduction in CD2 tetramers binding to its ligand 
CD58. 
Ligands for Spα were already reported in the literature. CD36 was the first molecule 
described as being a receptor for Spα endocytosis in macrophages [47]. CD36 recognizes 
multiple ligands allowing it to exert different functions. The ability of this protein to 
internalize modified lipoproteins like oxLDL and thus its association with the atherosclerosis 
is one of the most investigated functions. However, the nature of the Spα-CD36 binding and a 
possible modulation of the interaction of CD36 with other ligands remain largely unknown. In 
addition, an interaction of Spα with some regulators of complement activation (RCA) like 
CD55, Crry, CD59 and factor H was demonstrated by co-immunoprecipittation assays in 
transfected cells, even if further experimental evidences are needed to validate and 
characterize these interactions [72]. However, both CD36 and RCAs are not expressed in 
some of the cells positive for Spα binding in our screening, showing that other putative(s) 
ligand(s) exist adding another layer of complexity to the functions of this protein. 
Even though this ligand(s) remains unknown, the next approach, already in course, is 
to identify this molecule(s) by a transcriptomic analysis of all the cell lines and confirm the top 
candidates through molecular and cellular techniques. 
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Figure 18: hSpα tetramers binding to the different cell lines tested. A) A panel of cell lines (from non-
lymphoid, myeloblastic, monocytic and lymphoid lineages) were incubated with: i) streptavidin-Alexa647 
(negative control); ii) tetramers composed of Spα and streptavidin-Alexa647 (hSpα); and iii) CD2 tetramers 
containing Alexa647-coupled streptavidin (hCD2) in the absence or presence of 0.9 mM CaCl2 (+CaCl2) and 
analyzed by flow cytometry. B) Mean fluorescence intensity (MFI) of hSpa tetramers binding to the cells in the 
presence or absence of Ca2+ normalized to the streptavidin empty tetramers. C) MFI of hCD2 tetramers 
binding to the cells in the presence or absence of Ca2+ normalized to the streptavidin empty tetramers. 
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Figure 19: Binding of hSpα tetramers to cells after trypsin treatment. HCT116 and K562 cells were 
treated with 0.05 % trypsin for 20 min or left untreated. The cells were incubated with: i) streptavidin-Alexa647 
(negative control); ii) tetramers composed of Spα and streptavidin-Alexa647 (hSpα); and iii) CD2 tetramers 
containing Alexa647-coupled streptavidin (hCD2) in the absence or presence of CaCl2 (+ CaCl2) and analyzed 
by flow cytometry. 
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3. Insights into S4D-SRCRB localization and function 
 
3.1. S4D-SRCRB expression 
 
Very little is known about S4D-SRCRB. We started with the same approach used for 
Spα, using WB and ELISA of different protein lysates to detect S4D-SRCRB expression. 
However, we were unsuccessful in detecting this protein in all our vast attempts, probably due 
to the quality of the commercially available antibodies or the low expression of this protein. 
To circumvent this problem, other techniques were used in order to find more about the 
location of expression of this protein and function(s). 
The first approach was to analyze the expression of S4D-SRCRB, at the mRNA level, 
by PCR of cDNA of cells from different origins. S4D-SRCRB was detected in epithelial cells 
(HepG2, Caco-2, JEG-3, HEK 293T and HeLa) and in cells from hematopoietic origin (K562 
and Jurkat E 6.1). The expression was not detected in Raji, TCCSUP or in primary monocytes 
differentiated into MФs with GM-CSF or M-CSF as a way of inducing M1 and M2 
macrophages, respectively (Fig. 20). These findings are in accordance to Padilla et al., where by 
northern blotting analysis the expression of S4D-SRCRB was detected in K562, HeLa, 
HepG2 and HEK 293T [50]. In contrast with our results, these authors reported a lack of 
expression in Jurkat T cells that can be explained by a difference in the detection method. 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: S4D-SRCRB mRNA expression in cells from different origins. Agarose gel from the result of a 
PCR used to detect S4D-SRCRB mRNA expression. As control, β-actin amplification was used. 
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Immunohistochemistry technique can be used to identify structures within tissues but 
also molecules within the cells. Following this line of thought, this approach was used to 
characterize S4D-SRCRB expression in some human tissues. The anti-S4D-SRCRB antibody 
that did not work in WB or ELISA, revealed to be suitable for immunohistochemistry 
analysis. This human protein was found in several different human tissues like lung, thyroid, 
skeletal muscle, stomach, liver, kidney and placenta (Figs. 21, 22 and 23) but not all types of 
cells within these tissues express the protein. 
The lung histology (Fig. 21) revealed some tissue processing artifacts leading to some 
background after the antibody staining. However, there is a soft staining in pneumocytes from 
both types of epithelium (I and II). Type I pneumocytes form a thin barrier that enables gas 
exchange and at the same time prevents liquid passage. On the other hand, type II 
pneumocytes are responsible for the production of surfactant liquid, which prevents 
pulmonary alveolus from collapsing [73]. These two types of cells are in contact with 
substances from the exterior, which raises the question whether the presence of S4D-SRCRB 
protein is linked to the immune responses happening in the epithelial barriers of the lung. An 
alveolar macrophage present in the image corresponding to αS4D-SRCRB staining (indicated 
by a black arrow) does not seem to express this protein. 
The thyroid is an endocrine gland important for the synthesis of hormones and 
present plenty of follicles in its composition. S4D-SRCRB is slightly expressed in the 
cytoplasm of follicular cells of this organ. 
A skeletal muscle tissue sample was also analyzed for the expression of S4D-SRCRB. 
Surprisingly, S4D-SRCRB expression is clearly visible in the longitudinal section of skeletal 
muscle fibers presenting a “dotted” staining as illustrated in Fig. 21. 
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Figure 21: Photographs of histologic sections of lung, thyroid and skeletal muscle treated for S4D-
SRCRB protein detection. On the left are represented tissues stained with a negative control antibody and 
on the right those incubated with an anti-S4D-SRCRB antibody. Scale bars, 50 µm. 
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The “dotted” staining pattern revealing the expression of this protein is more evident 
in the stomach tissue. A very strong staining is present at the base of the stomach gland from 
the body portion. The cells that stand out are peptic cells that are producers of pepsinogen 
and lipase, presenting a very characteristic morphology due to the active synthesis and export 
of proteins (Fig. 22) [73]. Expression of S4D-SRCRB is also observed in a few parietal cells 
(oxyntic), responsible for H+ and Cl- secretion. 
The liver is the largest gland in the human body. This is an essential organ to 
neutralize and eliminate toxic substances. Analysis of the expression of S4D-SRCRB in this 
tissue reveals a strong staining in hepatocytes cytoplasm, but not in the interlobular connective 
tissue nor in central veins (Fig. 22). Hepatocytes have endocrine and exocrine functions and 
contribute to detoxification. In general, hepatocytes do not accumulate proteins in secretory 
granules intracellularly, they secrete proteins constantly into the blood stream [73]. This can 
explain why the “dotted” staining of S4D-SRCRB protein, observed in other tissues, is less 
visible in this organ. 
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Figure 22: Photographs of histologic sections from stomach and liver treated for S4D-SRCRB 
protein detection. . On the left are represented tissues stained with a negative control antibody and on the 
right those incubated with an anti-S4D-SRCRB antibody. Scale bars, 200 µm and 50 µm for a close view of 
the stomach histology. 
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 In the placenta, a strong staining at the cytoplasm of syncytiotrophoblast cells from 
the external cell layer of the chorionic villi reveals a high expression of S4D-SRCRB protein 
(green arrow in Fig. 23). Curiously, a macrophage from this tissue (Hofbauer cell) seems to 
express this protein as revealed by the “dotted” staining (black arrow) contrasting to the lack 
of expression of this protein in alveolar macrophages. A diffuse and less intense staining is 
observed throughout the intervillous space as shown in Fig. 23 (blue arrow). 
 The last histological tissue tested was the kidney. The histological section represented 
is from the cortical part, which is constituted by renal corpuscles (Bowman capsule and 
glomerulus), arterioles, proximal tubule, distal tubule, collector tubule and stellate veins. S4D-
SRCRB has a high expression in the epithelium of tubules, mainly in proximal tubules, 
responsible for the beginning of absorption and excretion process, not being expressed in 
renal corpuscles. 
In summary, these results indicate that S4D-SRCRB protein is mostly expressed in 
epithelial barriers demonstrated by PCR of different cell lines and by histological tissues 
analysis. These results are similar to those reported for human SSc5D and SCART1 proteins, 
members of SRCR B family. Both proteins are expressed in some epithelial tissues, such as 
kidney, placenta and stomach [74-76]. DMBT1 is also found in mucosal surfaces like lung, oral 
cavity, intestine, kidney and skin. This protein can be found in a secreted form, in the 
cytoplasm or on the cell surface. It is involved in the innate immune defense and it is 
considered a PRR [77, 78].  
Besides being expressed mainly in epithelial barriers, the staining pattern of S4D-
SRCRB protein has the characteristic of a dotted expression in certain tissues possibly 
indicating that the protein is stored in vesicles. In the future, tissue sections can be doubly 
stained with a lisossomal/endosomal marker and the anti-S4D-SRCRB antibody to analyze 
whether there is a co-localization indicative of in-vesicle storage of the protein. One 
interesting feature is its expression in the skeletal muscle, also with a “dotted” staining pattern, 
which transcends the view of its mucosal expression and is a characteristic never observed 
before for any of the other proteins from the SRCR B family. 
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Figure 23: Photographs of histologic sections from placenta and kidney stained for S4D-SRCRB 
protein detection. On the left are represented tissues stained with a negative control antibody and on the 
right those incubated with a monoclonal mouse anti-S4D-SRCRB antibody. In the placenta, S4D-SRCRB has 
a strong staining in the cytoplasm of syncytiotrophoblast cells from the external cell layer of the chorionic 
villi (green arrow). The black arrow points to a macrophage from this tissue (Hofbauer cell) that seems to 
express this protein. The blue arrow points to the diffuse and less intense staining throughout the intervillous 
space. Scale bars, 50 µm in the placenta images and 200 µm for kidney images. 
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3.2. Over-expression of S4D-SRCRB in cell lines 
 
Given the inability to use the commercially available antibodies in WB or ELISA 
based assays, we chose a strategy of S4D-SRCRB over-expression to try to uncover the 
functions of this protein. 
S4D-SRCRB was thus expressed in two cell lines: the epithelial Caco-2 cells and Jurkat 
E6.1 T cells. These two cells were chosen given the preferential expression of the protein in 
epithelial sites but also to analyze its putative function in a completely different context, in one 
of the cells that constitute the adaptive immune response, and therefore infer whether this 
protein can have different functions depending on the cells that express it. 
To overcome the antibody limitations, we cloned S4D-SRCRB in fusion with the HA 
tag and the fluorescent protein mCitrine in the C-terminal (Fig. 24) under the control of the 
spleen focus-forming virus (SFFV) promoter that allows the use of different experimental 
techniques. 
 
 
 
 
 
 
 
 
 
 
 
The resulting pHR-S4D-SRCRB-mCitrine was introduced in Caco-2 and Jurkat E6.1 
cells through lentiviral mediated transduction enabling its insertion in the genome and thus 
resulting in stably transfected cells expressing S4D-SRCRB constitutively (S4D-mCitrine). 
After transduction, the expression of the protein was analyzed by flow cytometry measuring 
mCitrine fluorescence (Fig. 25). The percentage of Caco-2 cells expressing S4D-mCitrine was 
33.5% and 42% for Jurkat E 6.1. To increase the homogeneity of the population of cells, cell 
sorting based on mCitrine fluorescence was performed. The results obtained in Fig. 25 show 
that > 97% of the recovered cells have a high expression of S4D-mCitrine. 
Figure 24: Schematic representation of the vector 
used to express the S4D-SRCRB protein. This protein 
was cloned in the pHR vector with a HA tag to facilitate 
WB detection and mCitrine for fluorescence assays, fused 
in the C-terminal of S4D-SRCRB. 
63 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To analyze whether S4D-mCitrine is secreted, supernatant of these two cell lines was 
collected when the cells were at ≈ 90% of confluence and tested with an anti-HA antibody by 
WB (Fig. 26). The supernatant of Caco-2 cells revealed the presence of S4D, indicating that 
not only the protein is being correctly expressed but also effectively secreted. Surprisingly, 
S4D was not found in the supernatant of Jurkat E6.1 cells, which may indicate that although 
being correctly expressed in these cells as demonstrated by the flow cytometry analysis in Fig. 
25, S4D-SRCRB secretion may be differently regulated in epithelial and lymphoid cells. 
Figure 25: S4D-SRCRB expression in Caco-2 and Jurkat T cells after lentiviral transduction. A) 
Histograms of Caco-2 cells before and after cell sorting showing mCitrine fluorescence. Caco-2 untransduced 
cells were used as control. B) Histograms of Jurkat T cells before and after cell sorting showing mCitrine 
fluorescence. Jurkat E6.1 untransduced cells were used as control. 
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We next assessed the pattern of expression and subcellular localization of S4D-
mCitrine in Caco-2 cells and Jurkat E6.1 cells by immunofluorescence microscopy (Fig. 27). 
The expression of S4D-SRCRB protein in both cells is, as expected, cytoplasmic even if a 
“dotted” staining is observed more markedly in Jurkat E6.1 cells, which is consistent with a 
possible localization on endosomal vesicles. These findings can be related with the presence of 
S4D-mCitrine in the supernatant of Caco-2 cells and absence in Jurkat E6.1 cells: it is 
conceivable that a more active secretion would reduce intracellular localization in secretory 
vesicles in Caco-2 cells and, in contrast, a reduced secretion could result in a more 
pronounced accumulation of the protein intracellularly in Jurkat E6.1 cells. Of note, this 
punctate pattern of expression of S4D-SRCRB is consistent with the one observed in the 
immunohistochemistry staining of diverse tissues detailed in the section above. 
 
 
 
 
 
Figure 26: Detection of S4D-mCitrine in the supernatant of Caco-2 
and Jurkat E6.1. S4D-mCitrine was detected with an anti-HA antibody. 
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Figure 27: Immunofluorescence images of Caco-2 and Jurkat E6.1 cells expressing S4D-mCitrine. Cells were stained with DAPI and phalloidin-TexasRed as a 
probe to F-actin. 
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3.3. Expression and secretion of S4D-SRCR during infection 
 
In a natural context, cells from the intestine are in contact with numerous 
microorganisms, acting as natural barriers preventing their access to the blood stream. Caco-2 
are epithelial cells from the colon, commonly used as a model of the intestinal barrier [79]. 
Diverse SRCR B molecules like CD163, DMBT1, CD5, CD6 and Spα, were already classified 
as PRR because they can bind to Gram-positive and negative bacteria and/or fungi. Some of 
these members also have the property to aggregate bacteria, which may prevent them from 
crossing the epithelial barrier [4, 80, 81]. Given the important role of these other members of 
the SRCR family as PRR and the fact that S4D-SRCRB is naturally expressed in Caco-2 cells, 
we wanted to know whether this protein would have any role in an infection context. In these 
preliminary experiments, two types of bacteria were used: the extracellular Escherichia coli and 
intracellular Listeria monocytogenes. 
Caco-2 cells expressing S4D-mCitrine were infected in vitro with E. coli and L. 
monocytogenes in a multiplicity of infection (MOI) of 50 for 1 h after which normal cell culture 
media containing antibiotics was added to the cells for extracellular elimination of bacteria, 
and this was considered time 0 of the experiment. Cells were then observed by fluorescence 
microscopy at time 0 and 2 h post-infection to compare the intracellular amount and 
localization of the protein within uninfected cells. Total lysates were simultaneously obtained 
for WB analysis. 
Western blot of lysates demonstrated that 2 h after interrupting the contact between 
E. coli or L. monocytogenes with Caco-2 cells, the intracellular amount of S4D-SRCRB decreases 
(Fig. 28). E. coli strain RS 218 is an extracellular pathogenic Gram-negative bacterium that is 
used as a prototype of a microorganism causing neonatal meningitis. Upon contact with the 
intestinal barrier, these bacteria can cause its disruption, reach the blood stream and migrate to 
the brain [82]. Listeria monocytogenes is an intracellular Gram-positive bacterium capable of 
crossing the intestinal barrier. The important virulence factors internalin A and B expressed 
on the L. monocytogenes bacterial surface can bind to membrane receptors of human epithelial 
cells mediating its invasion followed by actin polymerization and membrane remodeling [83]. 
Our results suggest that S4D-SRCRB seems to be somehow involved in the cell response to 
this inflammatory stimulus, being likely secreted. Immunofluorescence analysis of Caco-2 cells 
indicate that upon infection with E. coli (0 h) there is an increase in the punctate-like 
67 
 
localization of S4D-SRCRB, when compared with the uninfected cells or to those infected 
with L. monocytogenes, consistent with a possible increased accumulation in secretory vesicles 
that will then lead to the secretion of this protein (Fig. 29). The difference between the 
possible localization of S4D-mCitrine in endosomal vesicles in Caco-2 cells upon infection 
with E. coli and not in those infected with L. monocytogenes could reflect different cellular 
mechanisms triggered as a result of an infection by an extracellular vs. an intracellular 
pathogen. In addition, a decrease in the intracellular amount of S4D-mCitrine can be observed 
in the cells 2 h post-infection either with E. coli or L. monocytogenes, in agreement with the 
results obtained with WB analysis (Fig. 28). 
Caco-2 cells mimic an epithelial barrier and seem to secrete S4D-SRCRB. Our results 
indicate that the intracellular amount of this protein decreases intracellularly, probably due to 
secretion, being the first time that this protein could be implicated in this process. Considering 
that other members can interact with bacteria, this protein may have a similar role in infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: S4D-mCitrine intracellular levels upon Caco-2 infection. A) WB of total Caco-2 lysates from 
cells infected with E. coli or L. monocytogenes or untreated at 0 h and 2 h after infection to detect S4D-mCitrine 
levels using an anti-Ha antibody (top blot) or tubulin as loading control (bottom blot). B) Relative amount of 
S4D-mCitrine protein to tubulin upon activation, calculated by densitometry analysis of band intensity. The 
figure reflects one representative assay of multiple experiences made. 
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Figure 29: 
Immunofluorescence 
analysis of Caco-2 cells 
expressing S4D-mCitrine 
after infection. Cells were 
infected with E. coli or L. 
monocytogenes or left 
untreated, and were 
analyzed at 0 or 2 h after 
interrupting the contact 
between cells and bacteria. 
Cells were stained with 
DAPI and phalloidin-
TexasRed as a probe to F-
actin. 
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3.4. Activation of Jurkat T cells expressing S4D-mCitrine 
 
S4D-SRCRB mRNA was found in Jurkat E 6.1. To assess the function of this protein 
in T cells, over-expression was induced, as mentioned above. Similarly to what was performed 
for understanding the behavior of Spα in T cells under different activations, Jurkat cells 
transduced with the S4D-SRCRB construct were activated with αCD3/αCD28, PHA, PMA 
and ionomycin, or left untreated for 6 h. The activation of T cells was confirmed by the 
analysis of CD69 expression by flow cytometry. As a control, the same experiment was 
performed with Jurkat cells containing the empty vector (pHR-mCitrine). 
6 hours after activation with all treatments, a clear increase in the intracellular amount 
of S4D-SRCRB was induced, as demonstrated by WB using an anti-HA antibody (Fig. 30 A 
and B), where activation with PMA and ionomycin induced the higher increase in intracellular 
levels of S4D-mCitrine. Since the expression of the protein is under a foreign promoter and 
not the S4D-SRCRB endogenous promoter, this result can only be explained by a diminished 
secretion of this protein maybe due to intracellular interaction with some proteins, triggered 
by the activation of the T cells.  
The effects of S4D-mCitrine expression in the activation of Jurkat T cells were also 
analyzed by the expression of the early activation marker CD69. All treatments induced the 
expression of this marker upon activation in the pHR-mCitrine control cells, confirming the 
efficacy of the stimuli used (Fig. 30 C and D). However, the activation of Jurkat T cells 
expressing S4D-mCitrine was impaired after treatment with all the activators, being more 
evident when PHA and PMA+ionomycin were used. 
In basal conditions, Jurkat T cells did not seem to secrete S4D-SRCRB (Fig. 26), and 
upon T cell activation the protein amount in the cell is increased, which may suggest an 
intracellular role for this protein in the activation of the T cell. CD5 is capable of inhibiting 
the activation of the T cell through interaction of kinases involved in the signaling pathways 
downstream of TCR triggering [67]. In summary these observations raise the question about a 
possible role of S4D-SRCRB protein in the modulation of T cell activation. 
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Figure 30: Activation of Jurkat T cells expression S4D-mCitrine. Jurkat T cells transduced with pHR-S4D-
mCitrine or pHR-mCitrine as control were activated with anti-CD3 together with anti-CD28, PHA, PMA and 
ionomycin for 6 h or left untreated. A) WB of total lysates of Jurkat T cells expressing S4D-mCitrine detected 
with an anti-Ha antibody (top blot) or tubulin as loading control (bottom blot). B) Relative amount of S4D-
mCitrine protein to tubulin upon activation, calculated by densitometry analysis of band intensity. C) Activation 
of Jurkat T cells accessed by analysis of CD69 expression by flow cytometry. D) MFI of CD69 staining of the 
cells for each treatment. The MFI of CD69 staining for each treatment was normalized to the isotype control 
and divided to the MFI of untreated cells, thus obtaining a fold change after treatment. The figure reflects one 
representative assay of multiple experiences made. 
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4. S4D-SRCRB production and purification for ligand binding assays 
 
To perform the same binding experiments as those described for Spα, the same 
strategy was employed for S4D-SRCRB. CHOK1 stably expressing this protein with the same 
structure as recombinant Spα were already available (Fig. 31). 
Supernatants from these cells were collected and purified similarly as described for 
Spα by affinity chromatography using nickel media. However, and despite several attempts to 
optimize this process, the final result of purification was still unsuccessful characterized by low 
protein yields and a low degree of purity of the protein (Fig. 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Schematic representation of the plasmid used to produce recombinant S4D-SRCRB in 
CHO-K1 cells. The S4D-SRCRB cDNA was fused with an engineered signal peptide (RaduSP) allowing the 
recombinant protein to be secreted to the cell culture media, an HA and 6xHis tags for detection and 
purification, respectively. The protein also has a BirA recognition sequence in the C-terminal for in vitro 
biotinylation. 
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To overcome this problem, a new cell transfection approach was followed, using HEK 
293T cells due to their ease of transfection to produce the protein in a transient manner. 
Inherent to this method, the production of the protein was made in a shorter time and a 
smaller amount of supernatant was recovered, which allows for affinity chromatography to be 
performed using beads in a batch method. To assess the purity of the eluted fractions, an 
SDS-PAGE was performed together with WB to check whether the protein of interest was 
present in the elutate (Fig. 33). Unfortunately, although rS4D-SRCRB protein was present, the 
sample presented a high degree of impurity. Other attempts to purify this protein were made, 
but none of them were successful and since the contaminants present in the mixture had a 
similar molecular weight of the S4D-SRCRB protein, it was not possible to use the size 
exclusion technic. The second objective of this work, the search for possible ligands of S4D-
SRCRB protein was therefore not fulfilled. 
 
Figure 32: Affinity chromatography purification of S4D-SRCRB. On the left, a chromatogram 
demonstrating the different fractions collected during the washing and elution steps. S4D-SRCRB was eluted 
with a 100, 200 and 400 mM imidazole containing-buffer. On the top right panel, a SDS-PAGE containing 
selected fractions after staining with BlueSafe to check the purity of selected fractions. On the lower right is 
represented a WB to confirm the presence of this protein. 
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Figure 33: Purification of S4D-
SRCRB recombinant protein using a 
transient transfection. A) SDS-PAGE 
of the 3 fractions obtained after 
purification stained with Blue Safe for 
sample purity assessment. B) WB of the 
3 fractions using an anti-HA antibody to 
confirm the presence of the 
recombinant protein. 
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IV. CONCLUSION AND FUTURE PERSPECTIVES
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Spα has an important role in the immune system. Results obtained in this work point 
to a role in innate and adaptive immunity, once we observed for the first time its expression in 
other cells of epithelial and hematopoietic origin, as well as in serum and plasma, showing that 
it is not restricted to macrophages as reported. Besides the sites where this protein is 
expressed, the variation in its expression upon inflammatory (LPS) and anti-inflammatory 
(DEX) stimuli indicates that this protein has a role in macrophage responses. Besides that, we 
also demonstrated for the first time that Spα may have a role in adaptive immunity, suggesting 
that there is a pathway capable of rapidly altering the levels of Spα in T cells by affecting its 
secretion and/or production upon TCR stimulation. Furthermore, we have here detailed the 
binding of Spα to a multitude of cell lines highlighting the presence of a putative ligand (s) of 
protein nature where calcium plays an important role in this interaction. Ongoing work will 
allow the identification of this ligand (s) using an approach based on the transcriptome of the 
tested cell lines.  
S4D-SRCRB is closely linked to epithelial cells, which may indicate a role in innate 
immunity. The “dotted” pattern of staining suggests its storage in cytoplasmic vesicles. We 
have also demonstrated a variation in the intracellular levels of this protein upon infection 
suggesting a possible role in fighting pathogens at the level of the epithelial barriers. An 
intriguing finding was the association of S4D-SRCRB with T cell activation, thus unveiling a 
possible new role to this protein that seemed to be limited to the innate immune system. 
This investigation contributed with valuable new information concerning the sites 
and levels of expression of these two proteins upon different stimuli. Despite this, this work is 
a first approach for understanding the behavior of the proteins, especially for S4D-SRCRB 
whose function and characterization remains poorly defined. However, this work requires new 
experiments to clarify the observations made, especially more efforts should be done to assess 
whether changes in the intracellular levels are due to increased protein expression or increased 
secretion. The next step in the study of these proteins would be to dissect the signaling 
pathways that alter the expression of Spα in macrophages and in T cells. For S4D-SRCRB, 
new more sensitive methods for detecting endogenous protein are needed. Also, it would be 
interesting to discover the purpose of S4D-SRCRB expression in tissues like the skeletal 
muscle that could reveal a structural function for this protein. 
In conclusion, although preliminary in essence, this work provided important clues 
about the functions of these proteins that seem to be broader than initially expected.
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